

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

12

**EUROPEAN PATENT APPLICATION**

21 Application number: 84303783.9

51 Int. Cl.<sup>3</sup>: **C 12 N 15/00, C 12 P 21/00,**  
**A 61 K 37/36**

22 Date of filing: 05.06.84

30 Priority: 06.06.83 US 501353  
20.06.83 US 506078

71 Applicant: **GENENTECH, INC.**, 460 Point San Bruno  
Boulevard, South San Francisco California 94080 (US)

43 Date of publication of application: 19.12.84  
Bulletin 84/51

72 Inventor: **Lee, James Mon**, c/o P.O. Box 5058, South San  
Francisco California 94080 (US)  
Inventor: **Ullrich, Axel**, 433 Upper Terrace, San Francisco  
California 94117 (US)

84 Designated Contracting States: **AT BE CH DE FR GB IT**  
**LI LU NL SE**

74 Representative: **Armitage, Ian Michael et al, MEWBURN**  
**ELLIS & CO.** 2/3 Cursitor Street, London EC4A 1BQ (GB)

54 Human insulin-like growth factor (IGF) and human epidermal growth factor (EGF) produced from a recombinant host, process, expression vector and recombinant host therefor, and IGF-containing pharmaceutical composition.

57 Human IGF and EGF are prepared by recombinant DNA technology.

SEQUENCE LISTING

\*\*\*\*\*  
 (SEQ ID NO: 1) \*\*\*\*\*  
 \*\*\*\*\*  
 \*\*\*\*\*  
 \*\*\*\*\*

SEQUENCE LISTING

\*\*\*\*\*  
 \*\*\*\*\*  
 \*\*\*\*\*  
 \*\*\*\*\*  
 \*\*\*\*\*  
 \*\*\*\*\*  
 \*\*\*\*\*

SEQUENCE LISTING

\*\*\*\*\*  
 \*\*\*\*\*  
 \*\*\*\*\*  
 \*\*\*\*\*  
 \*\*\*\*\*

**EP 0 128 733 A1**

Field of the Invention

This invention relates to the preparation of human IGF (insulin-like growth factor), in various forms, via recombinant DNA technology. Notably, the present invention provides for the preparation of human IGF as a mature protein product of expression, processing, and secretion in a recombinant DNA modified host organism. This invention thus provides for the production, isolation, and use of human IGF, in its various forms, as well as to the associated recombinant DNA technology by which it is prepared. In addition, the present invention relates to the similar preparation of a related protein, human EGF (Epidermal Growth Factor).

The present invention arises in part from the discovery of a novel system by which human IGF can be prepared by a recombinant host organism in the form of a discrete, mature protein. This is accomplished according to one aspect of the present invention by an expression system which permits the expression of the amino acid sequence of human IGF fused with at least a portion of the yeast alpha factor signal sequence, followed by processing of said signal sequence, and secretion of mature human IGF protein into the medium supporting the host organism. Thus, this novel aspect of the present invention, it is believed for the first time, permits the preparation, isolation, and utilization of human IGF as a discrete, mature protein. The present invention, in its broad compass, however, covers the preparation of the amino acid sequence of human IGF in other recombinant systems including bacteria and cell culture and includes, therefore, the expression of human IGF DNA sequences providing not only mature human IGF but also fusion product derivatives containing the amino acid sequence of IGF as the essential component. All such products have been found to be biologically active, hence useful as intended.

The publications and other materials hereof used to illuminate the background of the invention, and in particular cases, to provide additional details concerning its practice are incorporated herein by this reference and for convenience, are alphabetically and numerically referenced in the following text and respectively grouped in the appended bibliography.

## 10     Background of the Invention

### A. Human IGF (Insulin-like Growth Factor)

Human IGF has been the subject of a fair amount of intensive study by past workers. A body of literature has been developed related to various aspects of this protein or series of proteins (see references A through L).

Insulin-like growth factors I and II have been isolated from human serum (A). The designation "insulin-like growth factor" or IGF was chosen to express the insulin-like effects and the insulin-like structure of these polypeptides which act as mitogens on a number of cells. The complete amino acid sequences of IGF-I and IGF-II have been determined (D,E). They are both single-chain polypeptides with three disulphide bridges and a sequence identity of 49 and 47 percent respectively, to human insulin A and B chains. The connecting peptide or C region is considerably shorter than the one of proinsulin and does not show any significant homology to it. (For a summary of earlier studies on the biological efforts of IGF, see Reference F).

IGF-I and IGF-II are growth promoting polypeptides occurring in human serum and human cerebral spinal fluid. Their structure is homologous to proinsulin. IGF-I seems to be produced by the liver along with a specific IGF-binding protein both of which are under

control of growth hormone. Thus, human IGF is considered to be an active growth promoting molecule that mediates the effect of human growth hormone.

5        It was perceived that the application of recombinant DNA and associated technologies would be a most effective way of providing the requisite large quantities of high quality human IGF for applied use to human beings as a growth factor. The goal was to produce human IGF either as biologically active fusion protein, or more  
10        importantly, as a mature protein, as products of recombinant DNA technology from a host organism. Such materials would exhibit bioactivity admitting of their use clinically in the treatment of various growth affected conditions.

15        B. Recombinant DNA Technology

Recombinant DNA technology has reached the age of some sophistication. Molecular biologists are able to recombine various DNA sequences with some facility, creating new DNA entities capable  
20        of producing copious amounts of exogenous protein product in transformed microbes and cell cultures. The general means and methods are in hand for the in vitro ligation of various blunt ended or "sticky" ended fragments of DNA, producing potent expression vehicles useful in transforming particular organisms, thus directing  
25        their efficient synthesis of desired exogenous product. However, on an individual product basis, the pathway remains somewhat tortuous and the science has not advanced to a stage where regular predictions of success can be made. Indeed, those who portend  
30        successful results without the underlying experimental basis, do so with considerable risk of inoperability.

DNA recombination of the essential elements, i.e., an origin of replication, one or more phenotypic selection characteristics, an expression promoter, heterologous gene insert and remainder vector,  
35        generally is performed outside the host cell. The resulting

recombinant replicable expression vehicle, or plasmid, is introduced into cells by transformation and large quantities of the recombinant vehicle obtained by growing the transformant. Where the gene is properly inserted with reference to portions which govern the transcription and translation of the encoded DNA message, the resulting expression vehicle is useful to actually produce the polypeptide sequence for which the inserted gene codes, a process referred to as expression. The resulting product may be obtained by lysing, if necessary, the host cell, in microbial systems, and recovering the product by appropriate purification from other proteins.

In practice, the use of recombinant DNA technology can express entirely heterologous polypeptides--so-called direct expression--or alternatively may express a heterologous polypeptide fused to a portion of the amino acid sequence of a homologous polypeptide. In the latter cases, the intended bioactive product is sometimes rendered bioinactive within the fused, homologous/heterologous polypeptide until it is cleaved in an extracellular environment. See references (M) and (N).

Similarly, the art of cell or tissue cultures for studying genetics and cell physiology is well established. Means and methods are in hand for maintaining permanent cell lines, prepared by successive serial transfers from isolate normal cells. For use in research, such cell lines are maintained on a solid support in liquid medium, or by growth in suspension containing support nutriments. Scale-up for large preparations seems to pose only mechanical problems. For further background, attention is directed to references (O) and (P).

Likewise, protein biochemistry is a useful, indeed necessary, adjunct in biotechnology. Cells producing the desired protein also produce hundreds of other proteins, endogenous products of the cell's metabolism. These contaminating proteins, as well as other

compounds, if not removed from the desired protein, could prove toxic if administered to an animal or human in the course of therapeutic treatment with desired protein. Hence, the techniques of protein biochemistry come to bear, allowing the design of separation procedures suitable for the particular system under consideration and providing a homogeneous product safe for intended use. Protein biochemistry also proves the identity of the desired product, characterizing it and ensuring that the cells have produced it faithfully with no alterations or mutations. This branch of science is also involved in the design of bioassays, stability studies and other procedures necessary to apply before successful clinical studies and marketing can take place.

#### Summary of the Invention

The present invention is based upon the discovery that recombinant DNA technology can be used successfully to produce human IGF and related protein, human EGF, preferably in direct form and in amounts sufficient to initiate and conduct animal and clinical testing as prerequisites to market approval. The products human IGF and EGF are suitable for use in all of their forms as produced according to the present invention, viz. in the prophylactic or therapeutic treatment of human beings for various growth associated conditions or diseases. Accordingly, the present invention, in one important aspect, is directed to methods of treating growth conditions in human subjects using human IGF or human EGF, and suitable pharmaceutical compositions thereof, prepared in accordance with the methods and means of the present invention.

• The present invention further comprises essentially pure, mature human IGF, as a product of expression, processing, and secretion in a recombinant host organism. Such human IGF is free from association with N-terminus amino acid sequence derivable from the expression systems that can be employed to prepare the material. Thus, while the present invention is directed to the preparation of

polypeptides comprising the amino acid sequence of IGF, a notable aspect of the present invention involves the production of the mature human IGF directly into the medium of the recombinant host organism employed. The present invention is also directed to replicable DNA expression vehicles harboring gene sequences encoding human IGF and human EGF in expressible form, to microorganism strains or cell cultures transformed with such vehicles and to microbial or cell cultures of such transformants capable of producing amino acid sequences of human IGF and human EGF. In still further aspects, the present invention is directed to various processes useful for preparing said genes sequences, DNA expression vehicles, microorganisms and cell cultures and specific embodiments thereof. Still further, this invention is directed to the preparation of fermentation cultures of said microorganisms and cell cultures.

#### Brief Description of the Drawings

Figure 1 represents the chemically synthesized DNA strands used in the construction of expression vectors for human IGF.

Figure 2 shows the completed double stranded DNA of Figure 1.

Figure 3 show the fragments of DNA of Figure 2 after restriction by EcoRI and PstI and Bam HI.

Figure 4 depicts the ligation of parts 1 and 2 of Figure 3 into PBR322.

Figure 5 show parts 3 and 4 of IGF-I right half.

Figure 6 depicts the ligation of parts 3 and 4 of Figure 5 into the vector of Figure 4.

Figure 7 shows a sequence of DNA and deduced fusion protein containing IGF-I.



Figure 8 shows a sequence of DNA and deduced short fusion protein containing IGF-I.

Figure 9 depicts a plasmid used in the present construction.

5

Figure 10 shows the DNA and protein sequence of IGF-I fused with alpha factor pre-pro sequence.

10

Figure 11 is a vector containing alpha factor promotor and pre-pro sequence fused to IGF-I.

Figure 12 shows the yeast invertase signal fused to IGF-I.

15

Figure 13 shows the parental plasmid containing the yeast PGK promotor.

Figure 14 depicts a yeast expression vector containing PGK promotor, invertase signal and human IGF-I gene.

20

Figure 15 is the synthetic DNA used to construct the coding sequence of mature human EGF.

Figure 16 depicts the yeast alpha factor "pre-pro" sequence fused to the human EGF coding sequence.

25

Figure 17 depicts the yeast invertase signal sequence fused to the human EGF coding sequence.

Figure 18 shows the coding sequence for human IGF-II.

30

### Detailed Description

#### A. Definitions

35

As used herein, "human IGF" and "human EGF" denotes human

insulin-like growth factor and human epidermal growth factor, produced by microbial or cell cultures systems and bioactive forms comprising the amino acid sequence corresponding to human IGF and human EGF otherwise native to human tissue. The human IGF and EGF proteins produced herein have been defined by means of DNA, gene, and deductive amino acid sequencing. It will be understood that inasmuch as natural allelic variations exist and occur from individual to individual, as demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions, or additions of one or more amino acids of said sequences, the present invention is intended to embrace of all such allelic variations of the two molecules involved. In addition, the location of and the degree of glycosylation depends upon the nature of the recombinant host organism employed and such variations as may occur are included within the ambit of this invention. Finally, the potential exists in the use of DNA technology for the preparation of various derivatives of human IGF and human EGF by simple modification of the underlying gene sequence for such molecules. Such modifications could be accomplished by means of site directed mutagenesis of the underlying DNA, as an example. All such modifications resulting in derivatives of human IGF and human EGF are included within the scope of the present invention so long as the essential characteristic human IGF and human EGF activities remain unaffected in kind.

"Essentially pure form" when used to describe the state of human IGF or human EGF produced by this invention means that the proteins are free of proteins or other materials normally associated with human IGF or human EGF when produced by non-recombinant cells, i.e. in their "native" environments.

"Expression vector" includes vectors which are capable of expressing DNA sequences contained therein, where such sequences are operably linked to other sequences capable of effecting their expression, i.e., promotor/operator sequences. In sum, "expression

vector" is given a functional definition: any DNA sequence which is capable of effecting expression of a specified DNA code disposed therein. In general, expression vectors of utility in recombinant DNA techniques are often in the form of "plasmids" which refer to  
5 circular double stranded DNA loops which in their vector form, are not bound to the chromosome. In the present specification, "plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which  
10 function equivalently and which become known in the art subsequently.

"Recombinant host cells" refers to cells which have been transformed with such vectors. Thus, the human IGF and human EGF  
15 molecules produced by such cells can be referred to as "recombinant human IGF" and "recombinant human EGF".

#### B. Host Cell Cultures and Vectors

20 The vectors and methods disclosed herein are suitable for use in host cells over a wide range of prokaryotic and eukaryotic organisms.

In general, of course, prokaryotes are preferred for cloning of DNA sequences in constructing the vectors useful in the invention.  
25 For example, E. coli K12 strain 294 (ATCC No. 31446) is particularly useful. Other microbial strains which may be used include E. coli strains such as E. coli B, and E. coli X1776 (ATCC No. 31537). The aforementioned strains, as well as E. coli W3110 (F<sup>-</sup>,  $\lambda$ <sup>-</sup>, prototrophic, ATCC No. 27325), bacilli such as Bacillus subtilis,  
30 and other enterobacteriaceae such as Salmonella typhimurium or Serratia marcesans, and various pseudomonas species may be used. These examples are, of course, intended to be illustrative rather than limiting.

35 In general, plasmid vectors containing replicon and control

sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. For example, E. coli is typically transformed using pBR 322, a plasmid derived from an E. coli species (Bolivar, et al., Gene 2: 95 (1977)). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR322 plasmid, or other microbial plasmid must also contain, or be modified to contain, promoters which can be used by the microbial organism for expression of its own proteins. Those promoters most commonly used in recombinant DNA construction include the  $\beta$ -lactamase (penicillinase) and lactose promoter systems (Chang et al, Nature, 275: 615 (1978), Itakura, et al, Science, 198: 1056 (1977); (Goeddel, et al Nature 281: 544 (1979)) and a tryptophan (trp) promoter system (Goeddel, et al, Nucleic Acids Res., 8: 4057 (1980); EPO Appl Publ No. 0036776). While these are the most commonly used, other microbial promoters have been discovered and utilized, and details concerning their nucleotide sequences have been published, enabling a skilled worker to ligate them functionally with plasmid vectors (Siebenlist, et al, Cell 20: 269 (1980)).

In addition to prokaryotes, eukaryotic microbes, such as yeast cultures may also be used. Saccharomyces cerevisiae, or common baker's yeast is the most commonly used among eukaryotic microorganisms, although a number of other strains are commonly available. For expression in Saccharomyces, the plasmid YRp7, for example, (Stinchcomb, et al, Nature, 282: 39 (1979); Kingsman et al, Gene, 7: 141 (1979); Tschemper, et al, Gene, 10: 157 (1980)) is commonly used. This plasmid already contains the trp1 gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example ATCC No. 44076 or PEP4-1 (Jones, Genetics, 85: 12 (1977)). The presence of the trp1 lesion as a characteristic of the yeast host cell genome then provides an

effective environment for detecting transformation by growth in the absence of tryptophan.

Suitable promoting sequences in yeast vectors include the  
5 promoters for 3-phosphoglycerate kinase (Hitzeman, et al., J. Biol. Chem., 255: 2073 (1980)) or other glycolytic enzymes (Hess, et al, J. Adv. Enzyme Reg., 7: 149 (1963); Holland, et al, Biochemistry, 17: 4900 (1978)), such as enolase, glyceraldehyde-3-phosphate  
dehydrogenase, hexokinase, pyruvate decarboxylase,  
10 phosphofructokinase, glucose-6-phosphate isomerase,  
3-phosphoglycerate mutase, pyruvate kinase, triosephosphate  
isomerase, phosphoglucose isomerase, and glucokinase. In  
constructing suitable expression plasmids, the termination sequences  
associated with these genes are also ligated into the expression  
15 vector 3' of the sequence desired to be expressed to provide  
polyadenylation of the mRNA and termination. Other promoters, which  
have the additional advantage of transcription controlled by growth  
conditions are the promoter regions for alcohol dehydrogenase 2,  
isocytochrome C, acid phosphatase, degradative enzymes associated  
20 with nitrogen metabolism, and the aforementioned glyceraldehyde-3-  
phosphate dehydrogenase, and enzymes responsible for maltose and

25

30

35

galactose utilization (Holland, *ibid.*). Any plasmid vector containing yeast-compatible promoter, origin of replication and termination sequences is suitable.

5        In addition to microorganisms, cultures of cells derived from multicellular organisms may also be used as hosts. In principle, any such cell culture is workable, whether from vertebrate or invertebrate culture. However interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture  
10        (tissue culture) has become a routine procedure in recent years [Tissue Culture, Academic Press, Kruse and Patterson, editors (1973)]. Examples of such useful host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, and W138, BHK, COS-7 and MDCK cell lines. Expression vectors for such cells ordinarily  
15        include (if necessary) an origin of replication, a promoter located in front of the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences.

20        For use in mammalian cells, the control functions on the expression vectors are often provided by viral material. For example, commonly used promoters are derived from polyoma, Adenovirus 2, and most frequently Simian Virus 40 (SV40). The early and late promoters of SV40 virus are particularly useful because  
25        both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication (Fiers, et al, Nature, 273: 113 (1978) incorporated herein by reference. Smaller or larger SV40 fragments may also be used, provided there is included the approximately 250 bp sequence extending from the Hind III site  
30        toward the Bgl I site located in the viral origin of replication. Further, it is also possible, and often desirable, to utilize promoter or control sequences normally associated with the desired gene sequence, provide such control sequences are compatible with  
35        the host cell systems.

An origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g. Polyoma, Adeno, VSV, BPV, etc.) source, or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.

### C. Methods Employed

If cells without formidable cell wall barriers are used as host cells, transfection is carried out by the calcium phosphate precipitation method as described by Graham and Van der Eb, Virology, 52: 546 (1978). However, other methods for introducing DNA into cells such as by nuclear injection or by protoplast fusion may also be used.

If prokaryotic cells or cells which contain substantial cell wall constructions are used, the preferred method of transfection is calcium treatment using calcium chloride as described by Cohen, F.N. et al Proc. Natl. Acad. Sci. (USA), 69: 2110 (1972).

Construction of suitable vectors containing the desired coding and control sequences employ standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to form the plasmids required.

Cleavage is performed by treating with restriction enzyme (or enzymes) in suitable buffer. In general, about 1 µg plasmid or DNA fragments is used with about 1 unit of enzyme in about 20 µl of buffer solution. (Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer.) Incubation times of about 1 hour at 37°C are workable. After incubations, protein is removed by extraction with phenol and chloroform, and the nucleic acid is recovered from the aqueous fraction by precipitation with ethanol.

If blunt ends are required, the preparation is treated for 15 minutes at 15° with 10 units of Polymerase I (Klenow), phenol-chloroform extracted, and ethanol precipitated.

5           Size separation of the cleaved fragments is performed using 6 percent polyacrylamide gel described by Goeddel, D., et al, Nucleic Acids Res., 8: 4057 (1980) incorporated herein by reference.

10           For ligation approximately equimolar amounts of the desired components, suitably end tailored to provide correct matching are treated with about 10 units T4 DNA ligase per 0.5 µg DNA. (When cleaved vectors are used as components, it may be useful to prevent religation of the cleaved vector by pretreatment with bacterial alkaline phosphatase.)

15           For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform E. coli K12 strain 294 (ATCC 31445), and successful transformants selected by ampicillin resistance where appropriate. Plasmids from the  
20           transformants are prepared, analyzed by restriction and/or sequenced by the method of Messing, et al, Nucleic Acids Res., 9:309 (1981) or by the method of Maxam, et al, Methods in Enzymology, 65:499 (1980).

#### Examples

25           The following examples are intended to illustrate but not to limit the present invention.

#### Synthesis and Expression of Human IGF-1

30           Enzymes were obtained from the following suppliers:  
            New England Biolabs: restriction enzymes, T4 DNA ligase  
            Bethesda Research Labs: restriction enzymes, Bact. Alkaline

35



## Phos.

Boehringer-Mannheim: E. coli DNA Polymerase I (Klenow)  
P+L Biochemicals: Polynucleotide kinase, Terminal  
Nucleotidyl Transferase

5

## New England Nuclear:

pBR322 [oligo(dG)-tailed] DNA

## Reagents:

10

BioRad: Bis Acrylamide, Acrylamide, TEMED

Sigma: Ammonium Persulfate

Amersham: 10218  $\gamma$   $^{32}\text{P}$  ATP >5000 Ci/mmol; 10165  $\alpha$   $^{32}\text{P}$  dCTP  
>400 Ci/mmol.

15

Solutions and Media: 1X TBE: .54M Tris Base, 0.54 M Boric  
Acid, .017 M  $\text{Na}_2\text{EDTA}$ .

Difco: Yeast Nitrogenous Base (YNB); Tryptone, Yeast  
Extract; Bacto-Agar; Casamino Acids.

## Autoradiography:

20

Kodak X-O mat AR XAR-2 Film

## Glass Beads:

0.45-0.50 mm B. Braun Melsungen AG

25

## LB medium (per liter):

10g NaCl; 5g yeast extract; 10g tryptone; .17ml NaOH (50  
percent)

30

## LB Agar (per liter):

10g tryptone; 5g yeast extract; .5g NaCl; 15g Bacto-Agar;  
adjusted to pH 7.5 with NaOH.

## Antibiotics:

35

Tetracycline (5  $\mu\text{g/ml}$ ) in all mediums; Ampicillin (20  $\mu\text{g/ml}$ )  
in all mediums (plates or liquid)

## Y9 Medium (per liter):

6g  $\text{Na}_2\text{HPO}_4$  (anhydrous); 1g  $\text{NH}_4\text{Cl}$ ; 3g  $\text{KH}_2\text{PO}_4$ ; .5g  
NaCl; 1 mM  $\text{MgSO}_4$ ; 0.5 percent (w/v) glucose; 0.5 percent  
(w/v) Casamino Acids; .0001 percent Thiamine-HCl.

5

## YNB-CAA (per liter):

6.7g Yeast Nitrogenous Base (without Amino Acids); 10 mg  
adenine; 10 mg uracil; 5g Casamino Acids; 20g Glucose.

10

## YNB-CAA agar plates (per liter):

Same as YNB-CAA + 30g agar.

## Standard Ligation Conditions:

15

10-fold molar excess of insert (or linker) to vector. 1X T4  
DNA ligase buffer and 400-800 U T4 DNA ligase; 14° - 12-16  
hours.

## Standard Kination Conditions:

20

1X Polynucleotide kinase buffer; 15 U polynucleotide kinase;  
37° 60 minutes; followed by reaction termination by heating  
to 65° for 10 minutes.

## 1X Kinase Buffer:

25

70 mM Tris-HCl (pH 7.6); 10 mM  $\text{MgCl}_2$ ; 5 mM DTT

## 1X T4 DNA Ligase Buffer:

50 mM Tris-HCl (pH 7.8); 10 mM  $\text{MgCl}_2$ ; 20 mM DTT; 1 mM rATP.

Construction, Strategy and Selection of a DNA Sequence.

30

The 1° protein structure of the human IGF-1 molecule has been  
determined (1). Based upon this protein sequence and the genetic  
code, a DNA sequence coding for mature human IGF-1 protein,  
including all possible base substitutions at any one base position,  
was determined by computer analysis (Genentech Untrans Program).

35

Using a restriction site analysis program (Genentech Asearch Program), all potential restriction sites located in all possible DNA sequences consistently coding for the same protein were found. Three sites internal to the coding sequence were selected: PstI, BamHI, and AuaI. Two additional sites were placed at the ends, just outside of the coding sequence of the mature protein: one EcoRI site before the initiation codon, AUG, and the SalI site following the termination codon, TAG of the coding sequence. The choice of these sites facilitated the cloning of the coding sequence in separate parts, each of which subsequently could be excised and then assembled to form an intact synthetic IGF-1 gene. This construction involved the assembly of 4 parts, 2 parts forming the left half, 2 parts forming the right half. Each part consisted of two single strands of chemically synthesized DNA (see Fig. 1). Proposed synthetic fragments were also analyzed for internal complementarity.

The constructions used to generate these four parts employed the use of DNA Polymerase I repair synthesis of synthetic oligonucleotide substrates having 9-10 bp stretches of complementary sequence at their 3' termini. In the presence of DNA Polymerase I (Klenow) and the four deoxynucleoside triphosphates, these primer-templates were extended to become full-length double-stranded DNAs. To prevent priming at locations other than the desired portions as well as self-hybridizations, each set of single-stranded DNAs were analyzed by a computer program (Genentech Homology Program), and wherever possible, sequences which would have potentially led to hairpin loops, self-priming, or mis-priming, were eliminated by alternate codon usage. Each of these four double-stranded DNAs were synthesized to include 9-12 additional bp of non-IGF-1 coding DNA at each end (see Fig. 2). This additional DNA was included to allow generation of sticky ends by restriction enzyme digestion. The sticky ends thus formed facilitated the ligation of the double-stranded pieces to contiguous coding sections of the synthetic gene or into a cloning vehicle.

The 9-12 extra bp of double stranded DNA beyond the restriction site at the end of each part (see Fig. 2) allowed for the TdT-mediated formation of single-stranded oligodeoxycytidine strands at the 3' ends of each double-stranded DNA section. These  
5 oligodeoxycytidine tailed double-stranded DNAs could then be annealed into a complementary oligodeoxyguanosine tailed PstI site of a cloning vehicle. Once cloned, and sequenced to ensure the correct base sequences, the parts could be easily isolated and ligated following restriction enzyme cleavage at the restriction  
10 sites selected at the ends of each of the four parts, to form the intact synthetic IGF-1 gene.

The method used successfully here was similar to that described by Rossi *et al.* (28); however, attempts at the construction and  
15 cloning of the IGF-1 coding sequence using the Rossi *et al.* method (28) with only two base pairs of extra DNA beyond the restriction enzyme recognition sites repeatedly failed. The method employed here also differs from the Rossi *et al.* procedure (28) in that restriction sites placed at both ends of a double stranded DNA allow  
20 for the convenience of cloning each double stranded DNA fragment, individually, by (dC)-tailing and annealing into a (dG)-tailed vector, a method which in practice requires less of the double stranded DNA than three-part ligations.

#### 25 Chemical Synthesis

Eight fragments, 43, 43, 46, 46, 46, 46, 54, and 46 bases in length (see Fig. 1), were chemically synthesized according to the  
30 method of Crea and Horn (2), the only change being the use of mesitylene nitrotriazole as the condensing agent rather than 2,4,6 Triisopropyl benzenesulfonylchloride tetrazole.

The syntheses of the fragments were accomplished from the appropriate solid support (cellulose) by sequential addition of the  
35 appropriate fully-protected dimer- or trimer-blocks. The cycles

were carried out under the same conditions as described in the synthesis of oligothymidilic acid (see Crea et al., supra). The final polymers were treated with base (aqueous conc.  $\text{NH}_3$ ) and acid (80 percent  $\text{HOAc}$ ), the polymer pelleted off, and the supernatant evaporated to dryness. The residue, dissolved in 4 percent aq.  $\text{NH}_3$ , was washed with ethyl ester (3X) and used for the isolation of the fully deprotected fragment.

Purification was accomplished by electrophoresis using 20 percent polyacrylamide gels. The pure oligonucleotide was ethanol precipitated following gel elution.

225-285 pmoles of each chemically synthesized fragment was mixed with an equivalent amount of the complementary single-stranded DNA fragment (i.e. 1L+3L; 2L+4L; 1R+3R, 2R+4R) in the presence of deoxyribonucleoside triphosphates at a final concentration of 200  $\mu\text{M}$  with the exception of dCTP. dCTP was added to a concentration of 5  $\mu\text{M}$  as a  $^{32}\text{P}$ -labeled isotope with a specific activity of 1000-2000 Ci/mmol) to allow easy monitoring of the repair-synthesis reaction product. The reactions were carried out in a buffer containing a final concentration of 50mM Tris HCl pH 7.5; 20 mM  $\text{MgCl}_2$ ; 20 mM DTT and 154 DNA Polymerase I (Klenow) in a reaction volume of 200  $\mu\text{l}$ . Reactions were allowed to proceed at 4° for 12-18 hrs.

Upon completion, EDTA was added to a concentration of 25 mM. Sample buffer containing the mixes were phenol extracted,  $\text{CHCl}_3$  extracted 2X, and products were etOH precipitated. Pellets were taken up in .3 M NaOAc and the DNA reprecipitated with etOH. After dissolving the pellets in  $\text{H}_2\text{O}$ , the 1L+3L and 2L+4L products were then digested separately with PstI in 100  $\mu\text{l}$  reaction mixes containing 1X PstI buffer (50mM  $(\text{NH}_4)_2\text{SO}_4$ , 20 mM Tris HCl pH 7.5, 10 mM  $\text{MgCl}_2$ ), and 70 U PstI. After 4 hrs, EDTA was added to a concentration of 10 mM, and the material was ethanol precipitated. Pellets were then taken up in .3 M NaOAc and reprecipitated, then taken up in  $\text{H}_2\text{O}$ . The PstI-digested 1L+3L

product was digested with EcoRI at 37° in a 100 µl reaction mix 1X EcoRI buffer (150 mM NaCl, 5 mM Tris HCl pH 7.5, 6 mM MgCl<sub>2</sub>) and 70 U EcoRI. The PstI digested 2L+4L product was digested at 37° with BamHI in a 100 µl reaction mix in 1X BamHI Buffer (150 mM NaCl, 5 mM Tris HCl pH 7.9, 6 mM MgCl<sub>2</sub>) and 70 U BamHI. After 4 hrs, EDTA was added to both mixtures, and sample buffer was added. They were electrophoresed on a 6 percent polyacrylamide slab gel. Six percent slab gels were cast with a mixture containing 6 percent (w/v) acrylamide (20 to 1 ratio of acrylamide to Bis acrylamide) 1X TBE, 1 percent APS and 0.1 percent TEMED. Reaction products were located on the gel by autoradiography and the band corresponding to the 45 bp EcoRI-PstI digested 1L+3L product (Part 1) (see Fig. 3) and the band corresponding to the 50 bp PstI-BamHI digested 2L+4L product (Part 2) (see Fig. 3) were excised from the gel, the material electroeluted in 0.2X TBE, phenol extracted, CHCl<sub>3</sub> extracted, and ethanol precipitated. Parts 1 and 2 were dissolved in H<sub>2</sub>O.

#### Cloning Vector Prep.

Cloning vector was prepared by digesting 20 µg pBR322 (15) with 50 U EcoRI and 50 U BamHI, in 1X RI Buffer at 37° for 6 hr. After addition of EDTA to a concentration of 10 mM, sample buffer was added, and the mixture was run on a 5 percent polyacrylamide gel. The gel was developed by staining 10' in H<sub>2</sub>O containing 5 µg/ml Et. Bromide, rinsing 2X in H<sub>2</sub>O and placing upon a UV transilluminator (302 nm). the band corresponding to the ca. 3712 bp EcoRI-BamHI digested pBR322 molecules was cut from the gel. The DNA was electroeluted from the gel slice, phenol extracted, CHCl<sub>3</sub> extracted 2X, and ethanol precipitated. The pellet was dissolved in H<sub>2</sub>O and was ready for ligation.

#### Ligation.

In a three-part ligation (see Fig. 4), in which the molar ratio

of inserts to vector in the ligation reaction was approximately 10 to 1, parts 1 and 2 were ligated into the EcoRI-BamHI digested 322 vector in 1X T4 DNA ligase buffer (cont. 50 mM Tris HCl pH 7.8; 10 mM MgCl<sub>2</sub>, 20 mM DTT, 1 mM rATP) and ~800 U T4 DNA ligase (NEB).

5 The reaction was carried out at 14° for 12-16 hrs.

### Transformations

10 E. coli strain 294 was used as the transformation host, using the procedure of M. Dagert and S.D. Ehrlich (3). The transformed cells were plated on LB-agar plates containing ampicillin (20 µg/ml; LB-Amp-plates) and transformants were screened and grown in LB medium containing ampicillin at 20 µg/ml ampicillin. Transformants were screened using a modification of the rapid miniscreen method of 15 Birnboim and Doly (4). Miniprep DNA prepared as such was digested with EcoRI and BamHI and run on polyacrylamide slab gels. Several transformants which illustrated a ca. 218 bp EcoRI-BamHI insert were grown in large scale and plasmids from each were isolated and sequenced according to the procedure of Maxam and Gilbert (5) to 20 confirm the correct chemical synthesis and construction. The pBR322 vector containing the complete correct left half sequence of IGF-1 was called IGF-1 LH 322 (see Fig. 5).

### Cloning of Fragments of the Right Half of IGF-1.

25 Using the identical conditions of DNA Polymerase I-mediated repair-synthesis, the two pairs of fragments comprising the right half of the synthetic IGF-1 were converted into double-stranded DNAs. After the DNA Polymerase I reactions, and without enzymatic 30 digestion, the 1R+3R (Part III) and 2R+4R (Part IV) reactions were run on a 6 percent polyacrylamide slab gels. The 83 bp (Part III) and 91 bp (Part IV) bands were located by autoradiography and cut from the gel. After electroelution the ethanol precipitated double-stranded DNAs were dC-tailed (see Fig. 6) using the 35 procedures of Villa-Komaroff et al. (6) and Rowenkamp and Firtel

(7). Reactions were carried out in 50  $\mu$ l vols. of 1X tailing mix (cont. .2M Pot. Cacodylate, 25 mM Tris HCl pH 5.9, 2 mM DTT, .5 mM  $\text{CoCl}_2$ ) and 22  $\mu$ M dCTP. After prewarming at 37° for 10', the 150 second reaction was begun by the addition of 10-20 units of terminal nucleotidyl transferase and terminated by addition of EDTA followed by phenol extraction,  $\text{CHCl}_3$  extraction 2X, and ethanol precipitation.

These oligo (dC) tailed Parts III and IV were then separately mixed with equimolar amounts of oligo (dG)-tailed PstI cut pBR322 vector in 50  $\mu$ l of 1X annealing buffer (.1M NaCl; 10 mM Tris HCl pH 7.8, 1 mM EDTA) at a final DNA concentration of 1-2  $\mu$ g/ml. After heating to 75°C, the mixes were gradually cooled to 4° over a period of 16 hr and the mix transformed into competent *E. coli* 294 cells prepared according to the procedure of Dagert and Ehrlich (3). Transformed cells were plated on LB-Tetracycline-Agar plates and grown in LB-Tetracycline medium at tetracycline concentrations of 5  $\mu$ g/ml. Tetracycline resistant transformants were picked and plated onto LB-Ampicillin-Agar plates to check for insertions at the PstI site. Several tetracycline resistant, Ampicillin-sensitive colonies for each Part 3 and 4 were miniscreened and those exhibiting insertions at the PstI locus were grown in large scale and sequenced by the Maxam and Gilbert technique (5) to confirm the correct DNA sequences of Parts 3 and 4.

#### Construction of an Intact Synthetic HuIGF-1 Coding Sequence

Preparation: Parts 3 and 4.

Parts 3 and 4 were separately removed from their vectors by digestions of 20  $\mu$ g of each vector with *Ava*II in 1X *Ava*II buffer (60 mM NaCl, 6 mM Tris-HCl (pH 8.0); 10 mM  $\text{MgCl}_2$ ; 6 mM 2-mercaptoethanol) and 30 U of *Ava*II. After 6 hr., at 37°, EDTA was added to the 150  $\mu$ l reactions to a concentration of 15 mM and the material phenol extracted,  $\text{CHCl}_3$  extracted 2X and ethanol



precipitated. The Part 3 pellet was then taken up in 1X BamHI buffer and digested in a volume of 150  $\mu$ l with 30 U BamHI at 37° for 4 hr. The pellet containing Part 4 was digested with 30 U SalI in 150  $\mu$ l of 1X SalI buffer at 37° for 4 hr.

5

Both digests were then run on 6 percent polyacrylamide slab gels and stained. The 51 bp band representing Part 3 and the 62 bp band representing Part 4 were removed from the gels and the DNA electroeluted, phenol extracted,  $\text{CHCl}_3$  extracted 2X and ethanol precipitated. Pellets were then taken up in  $\text{H}_2\text{O}$  and were ready for ligation.

10

#### Vector Preparation

15

20  $\mu$ g of the IGF-1 LH 322 vector was digested with 50 U of BamHI and 50 U of SalI in a 200  $\mu$ l reaction containing 1X BamHI buffer at 37° for 6 hr. After addition of EDTA to a concentration of 15 mM, the digestion mix was run on a 6 percent polyacrylamide slab gel, ethidium bromide stained and the 3814 bp band excised from the gel.

20

After electroelution, phenol extraction, chloroform extraction and ethanol precipitation, the DNA pellet was taken up in  $\text{H}_2\text{O}$  and was ready for ligation with Parts 3 and 4 in a three-part ligation. The ligation was performed under conditions described above for a three-part ligation (see Fig. 7). Parts 3 and 4 were present in the ligation mix at a 10-fold molar excess of inserts to vector. The mix was transformed into competent *E. coli* 294 cells prepared according to the Dagert and Ehrlich procedure (3) and plated onto LB-Ampicillin plates. Several transformants were miniscreened and two clones exhibiting a ca. 115 bp BamHI-SalI fragment were grown in large scale and their plasmids prepared. Both strands of the intact synthetic gene were sequenced by the Maxam-Gilbert technique (5) to confirm the correct sequence. The pBR322 plasmid containing the complete correct sequence coding for Human IGF-1 was called pBR322-HuIGF-1.

25

30

35

Human IGF-1 ExpressionIGF-1 Fusion Expression in Bacteria

Initial attempts were to obtain expression of IGF-1 as a fusion protein. To accomplish this, both the pNCV (9) and the pNCVsLE (10) expression vectors were used. (The pNCVsLE expression vector is a derivative of the pNCV vector and was prepared as follows: pNCV was treated with BglI, which cleaves at the 13 codon of the LE fusion. The site was converted to an EcoRI cleavage site using synthetic DNA, to give the expression vector pNCVsLE. The synthetic DNA introduced into the plasmid has the sequence:

5'-GATCCAGAATTC  
5' GATCGAATTCTG and this sequence was introduced  
into the plasmid:  
GATCCAGAATTC  
GTCTTAAGCTAG

15

As a strategy to release the fused human IGF-1 protein from the trp fusion protein, a linker was designed such that an enzymatic proteolysis method reported by Wunsch et al. (8) could be applied to this expression system. To accomplish this, a DNA linker:

20

ProAla  
5'-AATTCCTGCCG -3'  
3' GGGACGGCCAG-5'

25

30

was chemically synthesized by standard methods (2) which when linked to the trp fusion protein and the IGF-1 gene, coded for the amino acid residues Proline and Alanine followed by Glycine and Proline which are the first two amino acid residues of IGF-1 and preceded by Proline and Alanine together comprise a recognition site for a collagenase isolated from Clostridium histolyticum (11,12). This enzyme reportedly acts at such a site to cleave the alanine-glycine peptide bond.

35

To construct a DNA sequence coding for a fusion protein with a collagenase cleavage site, 30  $\mu$ g pBR322 HuIGF-1 plasmid was cleaved with 50 U BamHI and 50 U PvuI enzyme in 200  $\mu$ l 1X BamHI buffer at 37° for 6 hours. After addition of EDTA to a concentration of 15 mM, the reaction

mix was chromatographed on a 6 percent polyacrylamide slab gel. The smaller PvuI-BamHI fragment (~725 bp) was isolated and digested with 40 U Avall in 150  $\mu$ l 1X Sau96I buffer (60 mM NaCl, 6 mM Tris-HCl pH 7.4, 15 mM HgCl<sub>2</sub>, 6 mM 2-mercaptoethanol). After addition of EDTA to a concentration of 15 mM, the resulting mix chromatographed on a 6 percent polyacrylamide slab gel. The smaller Sau96I-BamHI fragment (~86 bp) was extracted from the gel, phenol extracted, chloroform extracted 2X, and ethanol precipitated. This fragment was ready for ligation.

200 pmols of linker fragments were kinased with 100 U polynucleotide kinase in 20  $\mu$ l of 1X polynucleotide kinase buffer (70 mM Tris-HCl (pH 7.6); 10 mM MgCl<sub>2</sub>; 5 mM DTT; 1 mM rATP) at 37° for 1 hour. The reaction was terminated by heating to 55°C for 5 minutes. 100 pmols of the kinased linker fragments were ligated to the 86 bp Sau96I-BamHI fragment with 400 U of T4 DNA ligase in 30  $\mu$ l of 1X T4 DNA ligase buffer at 14° for 12-16 hours. The ligation reaction was terminated by addition of EDTA to a concentration of 15 mM followed by phenol extraction, chloroform extraction 2X, and ethanol precipitation. The pellet was then taken up in 1X BamHI buffer and digested in a 100  $\mu$ l reaction with 50 U of EcoRI and 50 U of BamHI at 37° for 6 hrs. After terminating the digestion with EDTA, the mixture was chromatographed on a 6 percent polyacrylamide slab gel and the newly created (~97 bp) EcoRI-BamHI fragment was extracted from the gel, and prepared for ligation. The vector to receive this new fragment was prepared by digesting 30  $\mu$ g pBR322 HuIGF-1 with 100 U of each EcoRI and BamHI in 200  $\mu$ l of 1X BamHI buffer at 37° for 8 hr. The reaction was terminated, chromatographed on a 6 percent polyacrylamide slab gel and the larger band (~3830 bp) representing the EcoRI-BamHI digested plasmid was isolated and the plasmid DNA extracted and prepared for ligation as above. In a 30  $\mu$ l ligation reaction containing a 10-fold molar excess of insert fragment to vector, the EcoRI-BamHI fragment was ligated into the EcoRI-BamHI digested plasmid pBR322 HuIGF-1 under standard ligation conditions mentioned above. Competent *E. coli* 294, prepared as above (3), were used as transformation hosts and the transformed cells were plated onto LB-Ampicillin agar plates. Several transformants were picked,

miniscreened as above (4), and two exhibiting an EcoRI-BamHI insertion were grown in large scale and their plasmids purified. Using the Maxam-Gilbert procedure (5) the construction was sequenced to verify the correct synthesis and insertion of the EcoRI-Sau96I collagenase linker. This plasmid was called pBR322 HuSynIGF-1-M.

To prepare this EcoRI-SalI IGF-1 coding sequence for insertion into pNCV and pNCVsLE, 30 µg of pBR322 HuSynIGF-1-M was digested with 70 U of SalI in 200 µl of 1X SalI buffer (150 mM NaCl, 6 mM Tris-HCl (pH 7.9); 6 mM MgCl<sub>2</sub>; 6 mM 2-mercaptoethanol) at 37° for 6 hours. After addition of EDTA to 15 mM, the mixture was phenol extracted, chloroform extracted 2X, and ethanol precipitated.

Using standard chemical synthesis procedures (2) a SalI-EcoRI linker

5' TCGACGTACATG 3'  
3' GCATGTAATA 5'

was synthesized and 400 pmols kinased, as above. 200 pmols of the kinased linker was ligated to the SalI digested pBR322 HuSynIGF-1-M (prepared above) with 800 U T4 DNA ligase in 30 µl of 1X ligation buffer for 12-16 hours at 14°C.

After termination of the reaction with EDTA, the mixture was phenol extracted, chloroform extracted 2X, and ethanol precipitated. The pellet was then taken up in 1X EcoRI buffer and digested with 100 U EcoRI in a volume of 200 µl for 8 hours at 37°. After addition of EDTA to a concentration of 15 mM, the mixture was chromatographed on a 6 percent polyacrylamide slab gel. The gel was stained and the ~230 bp band corresponding to the EcoRI-EcoRI HuIGF-1 fragment was extracted from the gel, phenol extracted, chloroform extracted 2X, and ethanol precipitated. This fragment was ready for ligation into pNCV and pNCVsLE. pNCV and pNCVsLE were prepared for ligation by digestion of 20 µg of each with 100 U EcoRI in 200 µl 1X EcoRI buffer at 37° for 8 hours. After digestion, 200 U of bacterial alkaline phosphatase was added to each reaction and the mixtures warmed to 65°C for 2 hours. EDTA

was added to a concentration of 15 mM and the mixes were phenol extracted 3X, chloroform extracted 2X and then ethanol precipitated. These expression vectors were prepared for ligation.

5        Ligations of the EcoRI-EcoRI Human IGF-1 fragment into the two expression vectors were performed in 30  $\mu$ l reaction volumes in 1X T4 DNA ligase buffer with 800 U T4 DNA ligase at 14° for 12-16 hours. The EcoRI-EcoRI fragment was present at a 10-fold molar excess to vector.

10        Competent E. coli 294 were prepared (3) (ATCC 31446) and used as transformation hosts for the ligations. Transformed cells were plated onto LB-agar plates containing tetracycline (5  $\mu$ g/ml; LB-Tet-plates) and transformants were miniscreened (4). Miniscreen plasmid DNA from transformants of the pNCV-IGF-1 construction were digested with both PstI  
15        and BglII to determine the orientation of the EcoRI fragment insertions. Two clones whose plasmids contained a ~570 bp BglII-PstI fragment (as opposed to a ~690 bp fragment) were grown in large scale and their plasmids prepared. The construction was sequenced using the  
20        Maxam-Gilbert procedure (5) to confirm the correct insertion at the junction of the trp fusion and IGF-1 protein coding sequences as well as retention of the desired reading frame. Plasmids with the correctly inserted IGF-1 fragment were called pNCVLE-IGF-1. Transformants of the pNCV-sLE-IGF-1 construction were also miniscreened by the same procedure (5), and the plasmid DNAs were digested with HincII and PstI. Two clones  
25        exhibiting a ~150 bp HincII-PstI fragment (as opposed to a ~105 bp HincII-HincII fragment) were grown in large scale and their plasmids prepared. Using the Maxam-Gilbert techniques (5), the functions of the trp fusion and IGF-1 protein coding sequences were sequenced to ascertain proper orientation and retention of the proper reading frame. Those  
30        plasmids possessing the correct insertion and proper reading frame were called pNCV-sLE-IGF-1.

To attempt expression of each of these constructions, two clones, one possessing pNCV-IGF-1 and the other possessing pNCV-sLE-IGF-1, were  
35        inoculated into 10 ml M9-Tetracycline culture medium supplemented with

0.5 mg/ml Tryptophan. A clone containing pNCV-LE with no IGF-1 gene insert was also inoculated into culture medium to provide as a negative control in assays.

5        After 12-16 hours growth at 37° with agitation, 0.5 ml of these cultures were used to inoculate 250 milliliters of M9-Tetracycline culture medium. After growing for 12-16 hours at 37° with agitation, the cells were harvested by centrifugation at 5000 rpm for 10 minutes in a Sorvall GSA rotor. The refractile bodies were purified from the pelleted  
10       cells by: a) suspending the host cells in a buffered solution of ionic strength suitable to solubilize most of the host protein, b) subjecting the suspension to cell wall/membrane disruption, c) centrifuging the disrupted suspension at low speed to form a pellet, optionally repeating the foregoing steps, and d) recovering the heterologous protein as  
15       refractile bodies in the pellet (Reference 13). A small quantity of refractile particles of each of the three preparations was boiled in SDS and 2-mercaptoethanol containing sample buffer and run on SDS-polyacrylamide slab gels according to the Laemmli method (14). The size of the protein expressed by pNCV-IGF-1 (LE-IGF-1) was ~28,670  
20       Daltons (see Figure 7), and ~9770 Daltons for the pNCV-sLE-IGF-1 protein (sLE-IGF-1) (see Figure 8). These two expressed proteins were subjected to solubilization in 6M Guanidine-HCl followed by 50-fold dilution with dilute buffers. The final buffer for pNCV-IGF-1 after dilution was 0.12 M Guanidine-HCl; .05 M Tris-HCl pH 8, 20 percent glycerol; 0.1 mg/ml BSA; .15 M NaCl; 0.1 mM EDTA and the final buffer after dilution of the  
25       pNCV-sLE-IGF-1 refractile bodies was 0.14 M Guanidine-HCl; 25 mM Tris-HCl pH 7.6; 10 mM CaCl<sub>2</sub>. After spinning out particulate matter, the two solutions containing solubilized trp-IGF-1 fusion proteins were assayed by a radioimmune assay procedure of Furlanetto et al. (23), as modified  
30       by Hintz et al. (24). Both fusion proteins demonstrated activity in this assay. A negative control prep was also included in the assay and the control exhibited no measurable activity.

35

### Expression and Secretion in Yeast

To avoid the necessity of refractile body purification and solubilization, from bacterial cell lysates, yeast expression-secretion systems were sought as an alternative. Aside from the advantage of avoiding protein purification from cell lysates, coupled expression-secretion systems might obviate a subsequent in vitro processing step to remove a fused protein. Available were three yeast expression-secretion systems. These were: 1) yeast  $\alpha$  factor (22), employing yeast  $\alpha$ -factor promoter and preprosequence; 2) yeast invertase (15) consisting of the invertase promoter and signal sequence; and 3) a hybrid, composed of the PGK promoter (25) and invertase signal (16).

### Yeast Alpha-Factor Promoter Pre-Alpha Factor IGF-1 Plasmid Construction

To obtain expression of IGF-1 using the  $\alpha$  factor promoter and preprosequence, a plasmid constructed by Singh (22) was used. Plasmid P65 (Fig. 9) possesses sequences of the  $\alpha$ -factor promoter,  $\alpha$ -factor preprosequence, yeast 2 micron terminator, the yeast Trp 1 gene, as well as portions of the pBR322 plasmid. Due to the dearth of convenient restriction sites in the  $\alpha$ -factor preprosequence, to insert the IGF-1 coding sequence, the identical ~230 bp EcoRI-EcoRI HuSynIGF-1-M fragment that was ligated into pNCV and pNCVsLE (as mentioned previously in bacterial construction) was used. This EcoRI-EcoRI fragment contained the collagenase recognition site Proline-Alanine-Glycine-Proline, and allowed for collagenase digestion should IGF-1 be secreted as a fusion protein. The protein expressed in this construction (see Fig. 10) consists of the prepro  $\alpha$ -factor protein fused to IGF-1.

To insert the ~230 bp EcoRI-EcoRI fragment, the plasmid P65 was partially digested in 1X EcoRI buffer with EcoRI, and then sized upon a 0.7 percent horizontal agarose gel. The band corresponding to the linearized singularly restricted plasmid was excised, eluted from the gel, and phenol extracted, chloroform extracted 2X, and then ethanol precipitated. This DNA pellet was then taken up in 50 mM Tris-HCl (pH 8)

and treated with bacterial alkaline phosphatase under conditions to ensure 100 percent dephosphorylation of the 5' protruding ends. Following this treatment, the phosphatase activity was removed by first adding EDTA to a concentration of 15 mM, then extracting the DNA with phenol 3X, chloroform extracting 2X, and ethanol precipitating the vector. This material then contained linearized P65 vector, digested with EcoRI in either of two locations: one, either at the EcoRI site upstream of the  $\alpha$ -factor promoter and preprosequence, or at another, at the EcoRI site just downstream of the  $\alpha$ -factor promoter and preprosequence. The ~230 bp EcoRI-EcoRI IGF-1 fragment was ligated into the vector. The desired location of insertion was at the EcoRI site just downstream from the  $\alpha$ -factor promoter and preprosequence.

The ligation was carried out under standard ligation conditions and the transformation hosts were competent E. coli 294 prepared according to Dagert and Ehrlich (3). The transformed cells were plated onto LB-Amp-Agar plates. Several transformants were miniscreened according to the method of Birnboim and Doly (4), and plasmid DNA prepared as such was digested both Sall and HindIII in the appropriate buffers. One of several clones which contained a plasmid with an ~110 bp EcoRI-HindIII fragment was grown in large scale and its plasmid was purified. This plasmid, YEp9T  $\alpha$ -factor EcoRI-EcoRI IGF-1 (see Fig. 11), was used to transform competent yeast strain 20B-12 ( $\alpha$ trp pep4) cells according to the Hitzeman modification (19) of Hinnen et al. (17) and Beggs et al. (18) procedures.

Two such transformants, as well as a negative control transformant (with no IGF-1 insertion in the plasmid), were grown in suspension as were those of the yeast pre-invertase-IGF-1 plasmid transformations. Supernates were tested for secreted IGF-1 activity, as measured by the radioimmune assay procedure of Furlanetto et al. (23) as modified by Hintz et al. (24). Both supernates of transformants having plasmids with IGF-1 inserts contained IGF-1 activity and the negative control supernate did not. One of these transformants was grown in large scale in a 10 liter fermenter and the supernate contained secreted IGF-1 activity at a



peak level of  $\sim 3\mu\text{g/ml}$ . The IGF-1 activity of the fermentation supernate was also demonstrated by a placental membrane radioreceptor assay developed by Horner *et al.* (26).

#### 5 Yeast Invertase Promoter Signal IGF-1 Plasmid Construction

Based upon evidence of correct processing and secretion in yeast of proteins with heterologous signal sequences (16), the yeast invertase expression-secretion system became of interest. Attempted first was  
10 expression of the yeast invertase signal protein fused to IGF-1 (Fig. 12), coupled with the processing and secretion of IGF-1, using the invertase promoter as a starting point for transcription.

The yeast invertase signal coding sequence was attached to the IGF-1  
15 gene by the use of a *NcoI*-*HindIII* ( $\sim 400$  bp) fragment containing the initiation ATG codon and 5' end of the signal DNA sequence, and 4 DNA fragments synthesized by standard procedures (2):

20  
5' AGCTTTCCTTTTCCTTTTGGC 3'  
3' AAGGAAAAGGAAAACCGACCAA 5'

5' TGGTTTTGCAGCCAAAATATCTGCAG 3'  
3' ACGTCGGTTTTATAGACGTCCAG 5'

The construction began with the isolation of the 90 bp *AvaII*-*BamHI* IGF-1 left half fragment by *AvaII* digestion of a  $\sim 730$  bp *PvuI*-*BamHI*  
25 fragment isolated from *PvuI*-*BamHI* digested pBR322-HuSynIGF-1.

After phosphorylation of all four synthetic DNA fragments using standard kination conditions, the four synthetic fragments were mixed with the *AvaII*-*BamHI* IGF-1 left half fragment and ligated using standard  
30 ligation conditions. Following inactivation of the ligase by phenol and chloroform extraction 2X, the ethanol precipitated DNA pellet was dissolved and digested with *HindIII* and *BamHI* in the appropriate buffers. Newly constructed *HindIII*-*BamHI* (ca. 140 bp) fragment was isolated and extracted from a 6 percent polyacrylamide gel. This  
35 material was then ligated into *HindIII*-*BamHI* digested pBR322 vector,

which had been first digested with HindIII, then BamHI in the appropriate buffers, followed by purification of the 4014 bp vector fragment from a 6 percent gel.

5        The transformation host was competent E. coli 294 prepared by standard procedures (3) and the transformed cells were plated onto LB-Ampicillin agar plates. Several transformants were miniscreened by the Birnboim-Doly procedure (4) and their plasmid DNAs digested with EcoRI and BamHI. Two plasmids containing a ~167 bp EcoRI-BamHI fragment  
10        (illustrating the insertion of a 140 bp fragment into the HindIII and BamHI sites) were grown in large scale and their plasmids prepared. Using Maxam-Gilbert sequencing techniques (5), the entire 43 bp HindIII-AvaII section of DNA was sequenced to confirm the correct chemical synthesis and construction. The correctly constructed plasmid  
15        was called pBR322-P-I-HuSynIGF HindIII-BamHI (~4154 bp).

To insert the right half of the IGF-1 gene, this newly created plasmid was digested with BamHI-SalI in the appropriate buffers and the larger fragment (~3879 bp) was purified by gel fractionation. pBR322  
20        HuSynIGF was digested with BamHI-SalI in the appropriate buffers and the 115 bp BamHI-SalI fragment corresponding to the right half of the IGF-1 gene was isolated by gel fractionation. This 115 bp BamHI-SalI IGF-1 right half fragment was then ligated into the BamHI-SalI digested pBR322-P-I-IGF-1 LH HindIII-BamHI vector using standard ligation  
25        conditions. Competent E. coli strain 294 prepared according to Dagert and Ehrlich (3) were used as transformation hosts and transformed cells were plated onto LB-Amp-Agar plates. Several transformants were miniscreened using standard techniques (4) and plasmid DNA prepared as such was digested with EcoRI and SalI in the appropriate buffers and  
30        those plasmids illustrating an insertion of the BamHI-SalI fragment corresponding to the right half of IGF-1 were called pBR322 P-I-HuSynIGF-1 HindIII-SalI. One of the clones containing the pBR322 P-I-IGF-1 HindIII-SalI plasmid was grown in large scale and the plasmid was isolated. This plasmid was then digested with HindIII and SalI in  
35        the appropriate buffer to prepare a 255 bp HindIII-SalI fragment

containing all of the IGF-1 gene and the 3' portion of the yeast invertase signal coding sequence. This fragment of DNA was isolated by polyacrylamide gel fractionation and prepared for ligation by standard techniques.

5

The (~400 bp) NcoI-HindIII fragment containing the 5' end of the DNA sequence coding for the invertase signal as well as the yeast invertase promoter was created by NcoI and HindIII digestion of plasmid YIpsp-LeIFA (16) in the appropriate buffers. The YIpsp-LeIFA plasmid was first  
10 digested with NcoI to completion in the appropriate buffer, then phenol extracted, chloroform extracted 2X and ethanol precipitated. The linearized molecules were then taken up in 1X HindIII buffer and partially digested to generate the needed NcoI-HindIII (~400 bp) fragment which contains an internal HindIII restriction site. This NcoI-HindIII  
15 fragment was then isolated by gel fractionation and prepared for ligation using standard techniques.

To provide for a vector, plasmid pUC12-YI (EcoRI-BamHI) (16) was digested with NcoI and SalI in the appropriate buffers. After  
20 purification by gel fractionation, the ~2.6 kbp vector was eluted from the gel and prepared for ligation by standard techniques. To perform the final construction, a three-part ligation was arranged using standard ligation techniques. The DNA used in the ligation included the NcoI-SalI-digested pUC12-YI (EcoRI-BamHI) (16), the ~400 bp NcoI-HindIII  
25 and the ~255 bp HindIII-SalI fragments. After ligation, the material was transformed into competent *E. coli* 294 cells prepared according to Dagert et al. (3). Transformed cells were plated onto LB-Amp-Agar plates and several transformants were miniscreened using the procedure of Birnboim and Doly (4). Plasmid DNA prepared as such was digested with NcoI and  
30 SalI in the appropriate buffers and one of several clones containing plasmids exhibiting the insertion of a ~625 bp NcoI-SalI DNA fragment was grown in large scale and its plasmid was purified.

As a final step, this plasmid was linearized by digestion with SalI  
35 in the appropriate buffer. SalI-EcoRI linker, prepared as mentioned

above, and kinased under standard kination conditions, was ligated to the linearized vector to convert the Sall ends to EcoRI ends using standard ligation conditions. After termination of the ligation reaction by addition of EDTA to 15 mM, phenol extraction, chloroform extraction 2X and ethanol precipitation, the DNA pellet was dissolved in 1X EcoRI buffer, and digested with EcoRI. The EcoRI digestion released a ~1150 bp EcoRI fragment which contained the yeast invertase promoter, yeast invertase signal coding sequence and the IGF-1 coding sequence in one contiguous sequence. This material was isolated as a ~1150 bp band from a 6 percent polyacrylamide slab gel after fractionation and prepared for ligation using standard procedures.

The yeast-E. coli shuttle vector to receive this EcoRI fragment was prepared by EcoRI digestion of plasmid YEp9T (16) to linearize the vector, followed by treatment of the EcoRI termini with bacterial alkaline phosphatase using conditions recommended by the manufacturer to produce 100 percent dephosphorylation of the 5' protruding ends. The phosphatase reaction was terminated by addition of EDTA to 15 mM and the mixture phenol extracted 3X, chloroform extracted 2X, and then the DNA was ethanol precipitated. After redissolving the DNA pellet in 1X ligation buffer, the vector was mixed with the EcoRI ~1150 bp fragment and ligated under standard ligation conditions. Competent E. coli 294 cells prepared according to Dagert et al. (3) were used as transformation hosts and the transformants were plated onto LB-Amp-Agar plates. To determine the orientation of the insertion, several transformants were miniscreened using the method Birnboim and Doly (4) and plasmid DNAs purified as such were digested with BamHI in the appropriate buffer. One of several transformants possessing plasmids which produced a 1.3 kb BamHI-BamHI fragment upon BamHI digestion (as opposed to a ~475 bp fragment) was grown in large scale and its plasmid was purified. This plasmid, called P.I.IGF-1 EcoRI-EcoRI P.I. Promoter was used to transform competent yeast cells prepared essentially according to the methods of Hinnen, A., et al. (17), and Beggs, J.D. (18), but with the modifications of Hitzeman (19). The yeast strain 20B-12 (atrpl pep4) was used and was obtained from the Yeast Genetics Stock Center. In this construction, the

expression of IGF-1 begins with transcription at the invertase promoter and terminates in the yeast 2 micron sequence. The fusion protein expressed by this construction consisted of the yeast invertase signal fused to the IGF-1 protein, the combined molecular weight of which was 9964 Daltons. Another plasmid with the EcoRI fragment inserted in the reverse orientation was also used to transform competent yeast cells. In this construction, the IGF-1 was not provided with the yeast terminator.

Several transformants were picked and streaked on YNB-CAA agar plates. Among these, three transformants were picked and inoculated into 10 ml of YNB-CAA grow-up medium, in shake flasks. A fourth culture was also started using a colony transformed with the same vector, but with the EcoRI fragment inserted into the vector in the reverse orientation. After 16-20 hours growth at 30°, the cultures were sampled (1 ml) and cleared of cells by spinning 5' in an eppendorf microfuge. Supernatants were taken off and assayed for secreted activity using the radioimmune assay procedure of Furlanetto *et al.* (23) as modified by Hintz *et al.* (24). The supernates of the three transformants demonstrated activities of 1.7 to 3.3 ng/ml of IGF-1 activity and the negative control showed no activity. To determine intracellular activity, the pellets from 1 ml of culture were washed 1X in 25 mM Tris-HCl (pH 7.6), 1 mM EDTA and then lysed by 3-4 minutes of vigorous vortexing in 0.5 ml of the above Tris-EDTA solution with 0.4 ml of glass beads.

Assay of the cell lysates demonstrated IGF-1 activities of 1.5-2.8 ng/ml in the three IGF-1 secreting transformants and no activity in the negative control transformant. The highest secretor of the three transformants was grown in a 5 liter fermentation and the secreted IGF-1 activity reached a peak of 74 ng/ml of supernate.

#### Yeast PGK Promoter Pre-Invertase IGF-1 Plasmid Construction

One difficulty in the use of the invertase promoter was that it was subject to repression in the presence of glucose. Due to the incompatibility of glucose with high levels of transcription initiation

at the invertase promoter, the PGK promoter was sought as an alternative promoter, glucose, being the mainstay carbon source of fermentation processes.

5        To begin construction of the PGK promoter P.I.IGF-1 construction, it was necessary to clone a fragment containing the entire invertase signal coding sequence. To do this, plasmid pLeIF-A-Invertase Signal (16) was digested with BglII and then BamHI in the appropriate buffers. This digestion released several fragments, one of which was a ~625 bp  
10        BglII-BamHI fragment which was isolated from a 6 percent polyacrylamide slab gel and prepared for ligation using standard techniques. To clone this fragment, the pUC8 vector (20) was chosen as a cloning vehicle. pUC8 plasmid was digested with BamHI in 1X BamHI buffer, treated with bacterial alkaline phosphatase to dephosphorylate the 5' termini, and  
15        then run onto and purified from a 5 percent polyacrylamide slab gel.

After standard preparation for ligation the BamHI digested vector was mixed with the above ~625 bp BglII-BamHI fragment, and ligated under typical ligation conditions. The mixture was then transformed into  
20        competent *E. coli* 294 prepared by the Dagert *et al.* method (3) and the transformed culture plated onto LB-Amp-Agar plates. Several transformants were picked and miniscreened using the Birnboim and Doly (4) technique. Miniscreen plasmid DNA was digested with EcoRI and an analytical gel of the digests illustrated two types of plasmids having EcoRI fragments  
25        either ~260 bp or ~385 bp in length. One clone containing a ~260 bp EcoRI fragment was grown in large scale and its plasmid purified. This plasmid was called pUC8 P.I. Promotor-Signal BglII-BamHI.

A clone of this type was chosen because of the desired orientation of  
30        the inserted BglII-BamHI fragment. What was needed from this plasmid was an ~20 bp EcoRI-HindIII fragment containing the ATG initiation codon and 5' end of the invertase signal coding sequence.

To construct the intact invertase signal coding DNA sequence, ~150 bp  
35        HindIII-BamHI fragment containing the 3' end of the signal sequence fused

to the left half of the IGF-1 gene was isolated from HindIII-BamHI digestion of plasmid p8R322 P.I. IGF-LH HindIII-BamHI (~4154 bp). Isolation was by polyacrylamide slab gel fractionation, and the DNA band corresponding to the ~150 bp fragment was excised and prepared for ligation using standard techniques.

To obtain the short (~20 bp) EcoRI-HindIII fragment, the plasmid pUC8 P.I. Promotor-Signal-BglII-BamHI was digested with EcoRI in 1X EcoRI buffer. This digestion released the ~260 bp EcoRI-EcoRI fragment which was isolated from a 6 percent polyacrylamide slab gel after fractionation of the digestion mixture. This ~260 bp fragment was then digested with HindIII in the appropriate buffer, causing the creation of two HindIII-EcoRI fragments, one ~20 bp and the other ~240 bp in length. After complete digestion, the digestion was terminated by addition of EDTA to 15 mM and the entire mix phenol extracted, chloroform extracted 2X, and then ethanol precipitated.

A vector was prepared by EcoRI-BamHI digestion of p8R322 (15) in the appropriate buffers followed by purification of the EcoRI-BamHI digested vector from a 5 percent polyacrylamide slab gel. After preparation for ligation using standard techniques, the vector was mixed with the ~150 bp HindIII-BamHI fragment (3' end of invertase signal + Left Half IGF-1), and the two HindIII-EcoRI fragments (the ~20 bp fragment containing the 5' end of the invertase signal coding sequence), and the entire mixture was ligated under standard ligation conditions. Competent *E. coli* 294 prepared according to Dagert and Ehrlich (3) were used as transformation hosts for the ligation, and the transformed cells plated onto LB-Amp-Agar plates. Several transformants were miniscreened according to Birnboim and Doly (4) and the purified miniscreen DNAs were digested with EcoRI and BamHI. One of several clones possessing an ~170 bp EcoRI-BamHI fragment was grown in large volume and its plasmid purified. This plasmid contained the complete yeast invertase signal coding sequence fused to the left half of IGF-1 and was called P.I. IGF-1 L.H. RI-BamHI.

The desired ~170 bp EcoRI-BamHI fragment was isolated from this

plasmid by digestion of the plasmid with EcoRI and BamHI in the appropriate buffers followed by slab gel fractionation of the reaction mix. Using standard techniques, the ~170 bp band of DNA was prepared for ligation. To complete the construction, the right half of IGF-1 was isolated as an ~120 bp BamHI-EcoRI fragment from the plasmid P.I. IGF-1 EcoRI-EcoRI-P.I. Promoter by digestion with EcoRI and BamHI in the appropriate buffers followed by elution from a gel slice after polyacrylamide slab gel fractionation of the digestion mixture. These two fragments, the ~170 bp EcoRI-BamHI and the ~120 bp BamHI-EcoRI, were ligated together in vitro under standard ligation conditions, with both fragments present in roughly equimolar concentrations. This ligation mixture was then terminated by the addition of EDTA to ~15 mM followed by phenol extraction, chloroform extraction 2X, and ethanol precipitation. The DNA pellet was then taken up in 1X EcoRI buffer and digested with EcoRI. The digest was then run on a 6 percent polyacrylamide slab gel and the DNA band staining at ~290 bp (as opposed to ~340 bp and 240 bp) was excised and prepared for ligation using standard techniques. This ~290 bp EcoRI-EcoRI fragment contained the entire yeast invertase signal coding sequence fused to the complete IGF-1 coding sequence.

To express this protein, it was necessary to select a yeast vector with a promoter. The PGK promoter of the plasmid YEplPT Small (see Fig. 13) was used. YEplPT Small was constructed as a derivative of YEplPT (21) by ClaI and PvuII digestion of YEplPT in the appropriate buffers. The ClaI 5' protruding end was converted to a blunt end by use of DNA polymerase I (Klenow) under conditions recommended by the vendor. After blunting the ClaI protruding ends, the blunt ends ClaI and PvuII of the linearized vector were fused using T4 DNA ligase under standard ligation conditions. The resultant YEplPT small vector was ~5.9 kbp in size (or ~2.7 kbp smaller than YEplPT). Just as YEplPT, YEplPT small possesses the 2 micron origin and terminator, the PGK promoter, the TRP1 gene, and sequences from pBR322, including the  $\beta$ -lactamase gene.

YEplPT Small was employed as a vector by insertion of the ~290 bp EcoRI fragment into the unique EcoRI site of the plasmid. EcoRI



linearized YEplPT Small vector was prepared by EcoRI digestion of YEplPT small followed by bacterial alkaline phosphatase (BAP) treatment (to prevent religation of the complementary termini). The BAP was removed by phenol extraction 3X, chloroform extraction 2X, and ethanol precipitation. Under standard ligation conditions, the ~290 bp EcoRI fragment was ligated into the vector.

Competent *E. coli* 294 prepared according to Dagert and Ehrlich (3) were used as transformation hosts and the transformed culture was plated onto LB-Amp-Agar plates. Several transformants were miniscreened by the Birnboim and Doly procedure (4) and miniscreen plasmid DNAs were digested with HindIII in the appropriate buffer to determine the orientation of the insert. One of several transformants possessing a plasmid with a ~400 bp HindIII fragment was grown in large scale and its plasmid was purified. This plasmid was called YEplPT Small P.I. IGF-1 PGK promoter (see Fig. 14) and was used to transform competent yeast strain 20B-12 (ATCC 20625) ( $\alpha$ trp pep4) cells employing the Hitzeman modification (19) of Hinnen *et al.* (17), and Beggs *et al.* (18) procedures.

Several yeast transformants were grown in suspension in identical fashion as were those of the P.I. IGF-1 EcoRI-EcoRI P.I. promoter plasmid transformation and supernates were measured for activity determined by a radioimmune assay method of Furlanetto *et al.* (23) as modified by Hintz *et al.* (24). Shake flask supernates of three transformants contained activities ranging from 38 to 53 ng/ml of supernate. Similarly, one of these transformants was selected and grown in larger scale, utilizing a 10 liter fermenter and the secreted IGF-1 activity in the supernate reached a peak of ~780 ng/ml. This fermentation supernate was also subjected to a radioreceptor assay (26) and was demonstrated to contain IGF-1 activity.

#### Mature Human IGF Production

To construct a DNA sequence coding for the  $\alpha$ -factor pre-pro protein fused to the DNA sequence coding for mature IGF-I, an M-13 in vitro

mutagenesis technique was employed. (See Regin *et al.*, *Proc. Acad. Science (USA)* **75**, 4268; Hutchinson, *et al.*, *Journal Biological Chem.* **253**, 6551; Gilliam, *et al.*, *Gene* **8**, 81 and 99; Gillam, *et al.*, *Nucleic Acids Research* **5**, 2973; Adelman, *et al.*, *DNA* (June, 1983).)

5

To construct the M-13 plasmid, the plasmid YEp9T  $\alpha$ -factor ECoRI-ECoRI IGF-I (Figure 16) was digested with 8gl 11 and SalI and the ca. 1.5 Kbp fragment containing the  $\alpha$ -factor promotor-signal fused to IGF-I was isolated by polyacrylamide gel electrophoresis. This fragment was then ligated under standard ligation conditions to an MP-8 (BRL) vector digested with BamHI and Sal I, and treated with bacterial alkaline phosphatase. This ligation mix was then transformed into competent JM101 cells prepared according to the method of Dagert and Ehrlich (3). These transformants were then mixed with non-competent JM101 cells grown to log phase, mixed with top agar and plated onto LB agar plates. Several clear plaques were picked and sequenced using the M-13 dideoxy sequencing technique to confirm the presence of an insertion into the SalI-BamHI sites of the vector.

20

To perform the deletion according to the method above, a single strand of DNA of the sequence

5' AGAGTTTCCGGACCT CTT TTATCCAAAG 3'

25

was chemically synthesized by standard methods (2) and used to delete the DNA sequence

5' GAGGCTGAAGCTCTAGAATTCCTGCC 3'

3' CTCCGACTTCGAGATCTTAAGGGACGG 5'

30

just preceding the IGF-1 coding sequence of the  $\alpha$ -factor promotor/signal IGF-1 fusion sequence. This construction was then isolated as a replicative form, using a large scale plasmid preparation procedure from a JM101 cell culture inoculated with this plasmid containing the deletion.

35

The isolated replicative form (10 mg) was then digested with SalI.

Then phenol-chloroform extracted and then ethanol precipitated and prepared for ligation. To this replicative form was ligated Sal I-EcoRI linkers. After ligation and inactivation of the ligase by phenol, chloroform extraction followed by ethanol precipitation, the material was  
5 digested with ~50 U EcoRI enzyme under standard conditions and then run onto a 6 percent polyacrylamide gel. The ca. 1.5 kbp RI-EcoRI fragment released was isolated from the gel and prepared for ligation using standard conditions.

10 Yeast vector was prepared by digestion of 10 mg YEP9T plasmid with 50 units of EcoRI followed by treatment with bacterial alkaline phosphatase. The digestion was then repeatedly phenol-chloroform extracted and then ethanol precipitated and prepared for ligation.

15 The ca. 1.5 kbp EcoRI-EcoRI fragment containing the deletion was then ligated to the EcoRI-EcoRI YEP9T vector and the ligation mix was then transferred into competent 294 cells prepared according to the method of Dagert and Ehrlich (3) and miniscreened using the method of Birnboim and Doly (4). DNA prepared was screened by digestion with EcoRI and those  
20 DNAs illustrating an insertion of the ca. 1.5 kbp fragment were used to transform competent yeast strain 203-12 (ATCC 20526) according to the modification of Hitzeman (19) of the Hinner, et al., (17), and Beggs, et al., (18) procedures.

25 Transformants were then grown in shaker flasks and supernates assayed and shown to have IGF-I activity by the radioimmune assay procedure of Furlanetto, et al., (23) as modified by Hintz, et al., (24).

30 One of these clones were grown in large scale in a 10-liter fermentor and IGF-I purified from the supernatant of this fermentation. This material was then subjected to amino terminal protein sequencing and shown to be mature IGF-I protein.

35 Human EGF is prepared in accordance with invention following analogous procedures as those described above.

### Construction, Expression, and Secretion of Human EGF

In a fashion similar to IGF-1, double stranded DNA (Fig. 15) synthesized either by chemical means or through polymerization reactions was assembled to form a mature EGF coding sequence, with a codon coding for methionine (ATG) just preceding the amino-terminal asparagine found in the mature protein, and a codon (GTC) substituting valine for methionine at residue number 21 from the amino-terminal asparagine. This construction was then attached at the 5' end to an additional coding sequence, which when expressed in yeast or bacteria produced a fusion protein. This fusion protein was then susceptible to CNBr cleavage at the methionine to release the valine substituted human EGF molecule.

To secrete the mature form of EGF from yeast, the above sequence coding for the mature protein was attached to the  $\alpha$ -factor promoter/prepro sequence, the codon coding for valine at residue number 21 was replaced by ATG, and the appropriate deletion was made to bring the coding sequence for mature EGF adjacent to the  $\alpha$ -factor signal coding sequence (Figure 16). This construction was then inserted into the yeast vector Yep9T and transformed into yeast. Transformants produced as such expressed and secreted mature human EGF. In addition, the sequence coding for mature EGF was attached to the preinvertase signal sequence (Figure 17) and this construction, when inserted into the yeast vector Yep1PT small containing the PGK promoter, and transformed into yeast, resulted in the expression and secretion of human EGF.

### Construction, Expression, and Secretion of Human IGF-II

A double stranded DNA sequence coding for mature IGF-II was constructed from a combination of synthetic and natural DNA sequences (Figure 18). This coding sequence, which did not contain an internal methionine, was attached to the TrpE leader protein coding sequence and was expressed as a fusion protein. Mature IGF-II was chemically cleaved from the purified fusion product by the action of CNBr upon a methionine residue preceding the first residue (alanine) of the mature protein.

ons  
ig  
id  
his  
10  
5  
The IGF-II coding sequence was also attached to the  $\alpha$ -factor promoter/prepro sequence and after the appropriate deletion was made to bring the 3' end of the  $\alpha$ -factor signal coding sequence adjacent to the 5' end of mature IGF-II coding sequence, the construction was inserted into the Yep9T vector and transformed into yeast. Resultant transformants expressed and secreted mature human IGF-II. In the same manner, the sequence coding for mature IGF-II was attached to the preinvertase coding sequence. The resultant construction was inserted into YepIPT small and transformed into yeast. Transformants produced as such expressed and secreted mature human IGF-II.

#### Pharmaceutical Compositions

ng  
st  
1  
15  
20  
25  
The compounds of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the human IGF and human EGF or products hereof are combined in admixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation, inclusive of other human proteins, e.g. human serum albumin are described, for example, in Remington's Pharmaceutical Sciences by E. W. Martin, which is hereby incorporated by reference. Such compositions will contain an effective amount of the protein hereof together with a suitable amount of vehicle in order to prepare pharmaceutically acceptable compositions suitable for effective administration.

30  
35  
Notwithstanding that reference has been made to particular preferred embodiments of the present invention, it will be understood that the present invention is not to be construed as limited to such rather to the lawful scope of the appended claims.

Bibliography

- A. Rinderknecht, E. W. et al., Proceedings National Academy of Sciences (USA) 73, 2365 (1976).
- 5 B. Rinderknecht, et al., Proceedings National Academy of Sciences (USA) 73, 4379 (1976).
- C. Blundell, et al., Proceedings National Academy of Sciences (USA) 75, 1980 (1978).
- D. Rinderknecht, et al., Journal of Biological Chemistry 253, 2769 (1978), 2365 (1976).
- 10 E. Rinderknecht, et al., FEBS Letters 89, 283 (1978).
- F. Zaph, et al., Metabolism 27, 1803 (1978).
- G. Hintz, et al., Journal of Clinical Endocrinology and Metabolism 50, 405 (1980).
- 15 H. Blundell, et al., Nature 287, 781 (1980).
- I. Hintz, et al., Journal of Clinical Endo. and Metabolism 51, 672 (1980).
- J. Baxter, et al., Journal of Clinical Endo. and Metabolism 54, 474 (1980).
- 20 K. Hintz, et al., Journal of Clinical Endo. and Metabolism 54, 442 (1982).
- L. Schoenle, et al., Nature 296, 252 (1982).
- M. British Patent Application Publication No. 2007675A.
- N. Wetzel, American Scientist 68, 664 (1980).
- 25 O. Microbiology, Second Edition, Harper and Row Publications Inc., Hagerstown, Maryland (1973), especially pages 1122 et sequence.
- P. Scientific American 245, 106 (1981).
- 30 1. Rinderknecht, E. and Humbel, R.E., J. Biol. Chem. 253, 8, 2769-2776 (1978).
2. Crea, R. and Horn, T., Nucleic Acids Research 8, 2331-2348 (1980).
3. Dagert, M. and Ehrlich, S.D., Gene 6, 23-28 (1979).
4. Birnboim, H.C. and Doly, J., Nucleic Acids Research 7, 1513-1523 (1979).
- 35 5. Maxam, A. and Gilbert, W., Methods in Enzymology 65, 499 (1980).

6. Villa-Komaroff et al., Proc. Natl. Acad. Sci. USA 75, 3727 (1979).
7. Rowenkamp and Firtel, Dictyostelium Dev. Biol. 79, 409 (1980).
8. Wunsch, E. et al., Hoppe-Sayler's Z. Physiol. Chem. Bd. 362,  
S1285-1287 (Sept. 1981).
- 5 9. Maniatis, T. et al., Molecular Cloning, 426 (1982).
10. Kleid, D.G., Annals of New York Acad. Sci., Biochem. Eng., II, 413, 23-30,  
(1983)
11. Seifter, S. and Gallop, P.M., The Proteins, 2nd Ed. (H. Neurath, ed.)  
Vol. V, p. 659 (1966).
12. Nordwig, A., Leder 13, 10 (1962).
- 10 13. Lin, N. (U.S.S.N. 06/452,363, filed 22.12.82.) EPA 83307840.5.
14. Laemmli, U.K. Nature (London) 227, 680-685 (1970).
15. Bolivar, F. et al., Gene 2, 95 (1977).
16. Chang, C.N., (U.S.S.N. 06/488337 filed 25.4.83) EPA 84302722.8.
17. Hinnen, A. et al., Proc. Natl. Acad. Sci. USA 75, 1929-1933 (1978).
18. Beggs, J.D., Nature 275, 104-109 (1978).
19. EP 88632.
20. EP 88622.
- 20 21. Hitzeman, R.A. et al., Science 219, 620-625 (1983).
22. Singh, A. (U.S.S.N. 06/488323 filed 25.4.83) EPA 84302723.6.
23. Furlanetto, R.W., Underwood, L.E., Van Wyk, J.J., D'Ercole, A.J., J.  
Clin. Invest. 60, 648 (1977).
24. Hintz, R.L., Liu, F., Marshall, L.B., Chung, D., J. Clin. Endocrinol.  
Metab. 50, 405 (1980).
- 25 25. Hitzeman, R.A. et al., Proceedings of the Berkeley Workshop on Recent  
Advances in Yeast Molecular Biology: Recombinant DNA. U.C. Press,  
Berkeley, p. 173 (1982).
26. Horner, J.M., Liu, F., Hintz, R.A., J. Clin. Endocrinol. Metab. 47,  
6, p. 1287 (1978).
- 30 27. Rossi, J.J., Zierzek, R., Huang, T., Walker, P.A., Itakura, K., J.  
Biol. Chem. 257, 16, 9226 (1982).

CLAIMS

1. Mature human IGF, as a product of expression, processing, and secretion from a recombinant host.
- 5 2. Mature human IGF, as a product of recombinant yeast host expression with a N-terminus pre-sequence derived from yeast alpha factor DNA, processing of said pre-sequence and secretion of the mature human IGF into the medium supporting the recombinant yeast host.
- 10 3. Human IGF produced by recombinant host.
4. Human EGF produced by recombinant host.
- 15 5. A process for producing human IGF comprising preparing a replicable expression vector capable of expressing the DNA sequence encoding human IGF in a suitable host cell, transforming a host cell culture with said vector to obtain a recombinant host cell, culturing said recombinant host cell culture under conditions permitting expression of said human IGF encoded DNA sequence to produce human IGF and recovering said human IGF.
- 20 6. A process for producing human EGF comprising preparing a replicable expression vector capable of expressing the DNA sequence encoding human EGF in a suitable host cell, transforming a host cell culture with said vector to obtain a recombinant host cell, culturing said recombinant host cell culture under conditions permitting expression of said human EGF encoded DNA sequence to produce human EGF and recovering said human EGF.
- 25 7. An expression vector capable, in a transformant recombinant host, of expressing a DNA sequence encoding human IGF.
- 30
- 35



8. An expression vector capable, in a transformant recombinant host, of expressing a DNA sequence encoding human EGF.
9. A recombinant host transformed with the vectors of Claims 8 or 9.
10. A pharmaceutical composition consisting essentially of mature human IGF.

5

10

15

20

25

30

35

# Fig.1.

## Chemically Synthesized DNA - IGF-1

### IGF-1 LEFT HALF

1L (43-mer)

AGTTCTGATTTGGAATTCATGGGTCCGGAAACTCTGTGCGGC  
GACACGCCGGGACTCGACCAACTGCGAGACGTCTTAGTCTTGA

3L (43-mer)

2L (46-mer)

AGTTCTGATTCGCAGTTCGTATGTGGTGATCGAGGCTTCTACTTC  
GAAGATGAAGTTGTTTGGCTGACCCCATGCCCTAGGAGTTAGTCTTGA

4L (46-mer)

### IGF-1 RIGHT HALF

1R (46-mer)

GACTGACTTCTGGATCCTCCTCTCGTGGTGCTCCGCAACCGGCAT  
TTGGCCGTAGCAACTACTTACGACAAAAGCCAGGACATTTCAGTCAG

3R (46-mer)

2R (54-mer)

TGACTGACTTGGTCTGTGACCTTCGCCGTCTGGAAATGTACTGCGCTCCGCTG  
CGAGGCGACTTTGGCCGATTTCAGACGTATCAGCTGAGTTCAGTCAG

4R (46-mer)

Fig. 2.

## DNA Polymerase I Synthesized Double Stranded DNAs

## IGF-1 LEFT HALF

9 additional bases

12 additional bases

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  
 InIGlyProGluThrLeuCysGlyAlaGluLeuValAspAlaLeuGln  
 AGTCTGATTTTGAATTCATGGGTCGGAAACTCTGTGGCGCTGAGCTGGTTGACGCTCTGCAGAAATCAGAACT  
 TCAAGACTAAAGCTTAAGATACCCAGGCCTTTGAGACACGCCGCGACTCGACCAACTGCGAGAGCTCTTAGTCTTGA  
 PstI

Part 1

12 additional bases

11 additional bases

15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32  
 GlnPheValCysGlyAspArgGlyPheTyrPheAsnLysProThrGlyTyrGly  
 AGTCTGATTCGACGTTGATGTTGGTGTATCGAGGCTTCTACTTCAACAAACCGACTGGGTACGGATCCTCAATCAGAACT  
 TCAAGACTAAAGCGTCAAGCATACACCACCTAGCTCCGAAGATGAAGTTGTTGGCTGACCCATGCCCTAGGAGTTAGTCTTGA  
 BamHI

Part 2

## IGF-1 RIGHT HALF

12 additional bases

11 additional bases

33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51  
 SerSerArgArgAlaProGlnThrGlyIleValAspGluCysCysPheArgSer  
 GACTGACTTCTGGATCTCTCGTCGTGCTCCGCAACCGGCATCGTTGATGAATGCTGTTTCGGTCTCTGTAAGTCAGTC  
 CTGACTGAAGACCTAGGAGGAGGAGCAGCAGGCGGCTTTGGCCGTAGCAACTACTTACGACAAAGCCAGGCATTCAGTCAG  
 AvalII

Part 3

11 additional bases

10 additional bases

51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70  
 SerCysAspLeuArgArgLeuGluMetTyrCysAlaProLeuLysProAlaLysSerAlaIaTer  
 TGACTGACTTGGTCTGTGACCTTCGCCGCTCGAAATGTACTGGCTCCGCTGAACCCGGCTAAGTCTGCATAGTCGACCTCAAGTCAGTC  
 ACTGACTGAACCCAGGACACTGGAAGCGGCAGACCTTTACATGACCGGAGCGGACTTTGGCCGATTACAGCGTATCAGCTGAGTTTCAGTCAG  
 AvalII

Part 4

IGF-1 LEFT HALF

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  
 InIGlyProGluThrLeuCysGlyAlaGluLeuValAspAlaLeuGln  
AATTCATGGGTCGGAAACTCTGTCCGGCGCTGAGCTGGTTGACGCTCTGCAG  
 GATACCCAGGCCTTTGAGACACGCCGCGACTCGACCAACTGCGAGA PstI  
EcoRI

Part 1

16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31  
 pheValCysGlyAspArgGlyPheTyrPheAsnLysProThrGlyTyr  
TTCGTATGGTGATCGAGGCTTCTACTTCAACAACCGACTGGGTAC  
 CGTCAAGCATACACCACTAGCTCCGAAGATGAAGTTGTTGGCTGACCCATGCCCTAG BamHI  
PstI

Part 2

Fig.3.




Fig.4.

5/18


0128733

IGF-1 RIGHT HALF

33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51  
SerSerSerArgArgAlaProGlnThrGlyIleValAspGluCysCysPheArgSer  
GACTGACTTCTGGATCCTCTCGTCGTGCTCCGCAACCGGCATCGTTGATGAATGCTGTTTCGGTCTGTAAAGTCAGTCCCCCCCCCCCCCCCC  
Part 3 CCCCCCCCCCCCCCCCCCTGACTGAGACCTAGGAGGAGAGCAGCAGGCGGTTTGGCCGTAGCAACTACTTACGACAAAGCCAGGACATTTCAGTCAG  
BamHI  
AvaII

51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70  
SerCysAspLeuArgArgLeuGluMetIyrCysAlaProLeuLysProAlaLysSerAlaTer  
TGACTGACTTGGTCTCTGGACCTTCGCCGCTCGGAAATGTACTGCGCTCCGCTGAACCGGCTAAGCTGTCATAGTCGACTCAGTCAGTCCCCCCCCCCCCCCCC  
Part 4 CCCCCCCCCCCCCCCCCCTGACTGAACCCAGGACACTGGGAAGCGGCAGACCTTTACATGACGCCGAGGCGACTTTGGCCGATTTCAGCGTATCAGCTGAGTTCAGTCAG  
AvaII  
SalI

Fig. 5.

*Fig. 6.*

*Fig. 7.*

met lys ala ile phe val leu lys gly ser leu asp arg asp leu asp ser arg ile glu  
 ATG AAA GCA ATT TTC GTA CTG AAA GGT TCA CTG GAC AGA GAT CTC GAC AGC CGT ATT GAA  
  
 leu glu met arg thr asp his lys glu leu ser glu his leu met leu val asp leu ala  
 CTG GAA ATG CGT ACC GAT CAT AAA GAG CTG TCT GAA CAT CTG ATG CTG GTT GAT CTC GCC  
  
 arg asn asp leu ala arg ile cys thr pro gly ser arg tyr val ala asp leu thr lys  
 CGT AAT GAT CTG GCA CGC ATT TGC ACC CCC GGC AGC CGC TAC GTC GCC GAT CTC ACC AAA  
  
 val asp arg tyr ser tyr val met his leu val ser arg val val gly glu leu arg his  
 GTT GAC CGT TAT TCC TAT GTG ATG CAC CTC GTC TCT CGC GTA GTC GGC GAA CTG CGT CAC  
  
 asp leu asp ala leu his ala tyr arg ala cys met asn met gly thr leu ser gly ala  
 GAT CTT GAC GCC CTG CAC GCT TAT CGC GCC TGT ATG AAT ATG GGG ACG TTA AGC GGT GCG  
  
 pro lys val arg ala met gln leu ile ala glu ala glu gly arg arg arg gly ser tyr  
 CCG AAA GTA CGC GCT ATG CAG TTA ATT GCC GAG GCG GAA GGT CGT CGC CGC GGC AGC TAC  
  
 gly gly ala val gly tyr phe thr ala his gly asp leu asp thr cys ile val ile arg  
 GGC GGC GCG GTA GGT TAT TTC ACC GCG CAT GGC GAT CTC GAC ACC TGC ATT GTG ATC CGC  
  
 ser ala leu val glu asn gly ile ala thr val gln ala gly ala gly val val leu asp  
 TCG GCG CTG GTG GAA AAC GGT ATC GCC ACC GTG CAA GCG GGT GCT GGT GTA GTC CTT GAT  
  
 ser val pro gln ser glu ala asp glu thr arg asn lys ala arg ala val leu arg ala  
 TCT GTT CCG CAG TCG GAA GCC GAC GAA ACC CGT AAC AAA GCC CGC GCT GTA CTG CGC GCT  
  
 ile ala thr ala his his ala gln glu phe pro ala gly pro glu thr leu cys gly ala  
 ATT GCC ACC GCG CAT CAT GCA CAG GAA TTC CCT GCC GGT CCG GAA ACT CTG TGC GGC GCT  
  
 glu leu val asp ala leu gln phe val cys gly asp arg gly phe tyr phe asn lys pro  
 GAG CTG GTT GAC GCT CTG CAG TTC GTA TGT GGT GAT CGA GGC TTC TAC TTC AAC AAA CCG  
  
 thr gly tyr gly ser ser ser arg arg ala pro gln thr gly ile val asp glu cys cys  
 ACT GGG TAC GGA TCC TCC TCT CGT CGT GCT CCG CAA ACC GGC ATC GTT GAT GAA TGC TGT  
  
 phe arg ser cys asp leu arg arg leu glu met tyr cys ala pro leu lys pro ala lys  
 TTT CGG TCC TGT GAC CTT CGC CGT CTG GAA ATG TAC TGC GCT CCG CTG AAA CCG GCT AAG  
  
 ser ala AM  
 TCT GCA TAG TCGACGTACATGAA

Translated Mol. Weight = 28671.51

Underscored - Mature Human IGF-1

Boxed - Collagenase Recognition Site



sLE-IGF-1 Fusion Protein*Fig. 8.*

```

      1                                10
met lys ala ile phe val leu lys gly ser leu asp arg asp pro glu phe
ATG AAA GCA ATT TTC GTA CTG AAA GGT TCA CTG GAC AGA GAT CCA GAA TTC

      20                                30
pro ala gly pro glu thr leu cys gly ala glu leu val asp ala leu gln phe val cys
CCT GCC GGT CCG GAA ACT CTG TGC GGC GCT GAG CTG GTT GAC GCT CTG CAG TTC GTA TGT

      40                                50
gly asp arg gly phe tyr phe asn lys pro thr gly tyr gly ser ser ser arg arg ala
GGT GAT CGA GGC TTC TAC TTC AAC AAA CCG ACT GGG TAC GGA TCC TCC TCT CGT CGT GCT

      60                                70
pro gln thr gly ile val asp glu cys cys phe arg ser cys asp leu arg arg leu glu
CCG CAA ACC GGC ATC GTT GAT GAA TGC TGT TTT CGG TCC TGT GAC CTT CGC CGT CTG GAA

      80                                89
met tyr cys ala pro leu lys pro ala lys ser ala AM
ATG TAC TGC GCT CCG CTG AAA CCG GCT AAG TCT GCA TAG

```

Underscored - Mature Human IGF-1

Boxed - Collagenase Recognition Site




Fig. 9.

10/18

0128733

Yeast prepro  $\alpha$  factor - IGF-1

*Fig.10.*

met arg phe pro ser ile phe ser ala val leu phe ala ala ser ser ala leu ala ala  
ATG AGA TTT CCT TCA ATT TTT AGT GCA GTT TTA TTC GCA GCA TCC TCC GCA TTA GCT GCT

pro val asn thr thr thr glu asp glu thr ala gln ile pro ala glu ala val ile gly  
CCA GTC AAC ACT ACA ACA GAA GAT GAA ACG GCA CAA ATT CCG GCT GAA GCT GTC ATC GGT

tyr ser asp leu glu gly asp phe asp val ala val leu pro phe ser asn ser thr asn  
TAC TCA GAT TTA GAA GGG GAT TTC GAT GTT GCT GTT TTG CCA TTT TCC AAC AGC ACA AAT

asn gly leu leu phe ile asn thr thr ile ala ser ile ala ala lys glu glu gly val  
AAC GGG TTA TTG TTT ATA AAT ACT ACT ATT GCC AGC ATT GCT GCT AAA GAA GAA GGG GTA

ser leu asp lys arg glu ala glu ala leu glu phe pro ala gly pro glu thr leu cys  
TCT TTG GAT AAA AGA GAG GCT GAA GCT CTA GAA TTC CCT GCC GGT CCG GAA ACT CTG TGC

gly ala glu leu val asp ala leu glu phe val cys gly asp arg gly phe tyr phe asn  
GGT GCT GAA CTG GTT GAC GCT CTG GAG TTC GTA TGT GGT GAC CGT GGC TTT TAC TTC AAC

lys pro thr gly tyr gly ser ser ser arg arg ala pro gln thr gly ile val asp glu  
AAA CCG ACT GGT TAC GGA TCC TCC TCT CGT CGC GCT CCG CAA ACT GGC ATC GTT GAT GAA

cys cys phe arg ser cys asp leu arg arg leu glu met tyr cys ala pro leu lys pro  
TGC TGT TTT CGT TCT TGT GAC CTG CGC CGT CTG GAA ATG TAC TGC GCT CCG CTG AAA CCG

ala lys ser ala Term  
GCT AAG TCT GCA TAG

Underscored - Mature Human IGF-1

Boxed - Collagenase Recognition Site




Fig.11.

*Fig.12.*Yeast Invertase Signal - IGF-1 Protein

```

1      met leu leu gln ala phe leu phe leu ala gly phe ala ala lys ile
    ATG CTT TTG CAA GCT TTC CTT TTC CTT TTG GCT GGT TTT GCA GCC AAA ATA

10

20      ser ala gly pro glu thr leu cys gly ala glu leu val asp ala leu gln phe val cys
    TCT GCA GGT CCG GAA ACT CTG TGC GGC GCT GAG CTG GTT GAC GCT CTG CAG TTC GTA TGT

30

40      gly asp arg gly phe tyr phe asn lys pro thr gly tyr gly ser ser arg arg ala
    GGT GAT CGA GGC TTC TAC TTC AAC AAA CCG ACT GGG TAC GGA TCC TCC TCT CGT CGT GCT

50

60      pro gln thr gly ile val asp glu cys cys phe arg ser cys asp leu arg arg leu glu
    CCG CAA ACC GGC ATC GTT GAT GAA TGC TGT TTT CGG TCC TGT GAC CTT CGC CGT CTG GAA


70


80      met tyr cys ala pro leu lys pro ala lys ser ala AM
    ATG TAC TGC GCT CCG CTG AAA CCG GCT AAG TCT GCA TAG

89

```

Underscored - Mature Human IGF-1

*Fig.13.*

*Fig. 14.*

## HUMAN EGF

ecoRI  
 GAATTCATGA ACTCTGACTC TGAATGTCCA TTATCGCATG ATGGGT  
 CTTAAGTACT TGAGACTGAG ACTTACAGGT AATAGCGTAC TACCCA

rsal  
 ACTG TTTGCACGAC GG  
 TGAC AAACGTGCTG CCTCA

hinfI  
 AGTCTGTA TGTATATTGA AGCT  
 GACAT ACATATAACT TCGAGATC

xbaI  
 CTAGAC AAGTACGCTT GTAAGTGTGT TGTTGGTTAC ATCGGTGAAA GATGTCAATA CAGA  
 TG TTCATGCGAA CATTGACACA ACAACCAATG TAGCCACTTT CTACAGTTAT GTCTCTAG

sau3AI  
 bgIII  
 GATCTA AAGTGGTGGG AATTGAGATA GATTGAATTG AATTGAAATC GATTAAAGCT T  
 AT TTCACCACCC TTAAGTCTAT CTAAGTTAAC TTAAGTTTAG CTAATTTTCA A

Fig.15.



Yeast prepro  $\alpha$  factor - EGF

Fig.16.

16/18

0128733

met arg phe pro ser ile phe ser ala val leu phe ala ala ser ser ala leu ala ala  
ATG AGA TTT CCT TCA ATT TTT AGT GCA GTT TTA TTC GCA GCA TCC TCC GCA TTA GCT GCT

pro val asn thr thr thr glu asp glu thr ala gln ile pro ala glu ala val ile gly  
CCA GTC AAC ACT ACA ACA GAA GAT GAA ACG GCA CAA ATT CCG GCT GAA GCT GTC ATC GGT

tyr ser asp leu glu gly asp phe asp val ala val leu pro phe ser asn ser thr asn  
TAC TCA GAT TTA GAA GAA GGG GAT TTC GAT GCT GGT TTG CCA TTT TCC AAC AGC ACA AAT

asn gly leu leu phe ile asn thr thr ile ala ser ile ala ala lys glu glu gly val  
AAC GGG TTA TTG TTT ATA AAT ACT ACT ATT GCC AGC ATT GCT GCT AAA GAA GAA GGG GTA

ser leu asp lys arg asn ser asp ser glu cys pro leu ser his asp gly tyr cys leu  
TCT TTG GAT AAA AGA AGA AAC TCT GAC TCT GAA TGT CCA TTA TCG CAT GAT GGG TAC TGT TTG

his asp gly val cys met tyr ile glu ala leu asp lys tyr ala cys asn cys val val  
CAC GAC GGA GTC TGT ATG TAT ATT GAA GCT CTA GAC AAG TAC GCT TGT AAC TGT GGT GTT

gly tyr ile gly glu arg cys gln tyr arg asp leu lys trp trp glu leu arg AM  
GGT TAC ATC GGT GAA AGA AGA TGT CAA TAC AGA GAT CTA AAG TGG TGG GAA TTG AGA TAG

### Yeast Preinvertase - EGF

-19-  
met leu leu gln ala phe leu phe leu leu ala gly phe ala ala lys ile  
ATG TTG TTG CAA GCT TTC TTG TTG TTC TTT GGT TTC GCT GCT AAG ATC

GAATTTCATG

1                      -10  
ser ala asn ser asp ser glu cys pro leu ser his asp gly tyr cys leu his asp gly  
TCT GCT AAC TCT GAC TCT GAA TGT CCA TTA TCG CAT GAT GGG TAC TGT TTG CAC GAC GGA

20                      10                      30  
val cys met tyr ile glu ala leu asp lys tyr ala cys asn cys val val gly tyr ile  
GTC TGT ATG TAC ATT GAA GCT CTA GAC AAG TAC GCT TGT TGT AAC TGT GGT TAC ATC

40                      50                      53  
gly glu arg cys gln tyr arg asp leu lys trp trp glu leu arg AM  
GGT GAA AGA TGT CAA TAC AGA GAT CTA AAG TGG TGG GAA TTG AGA TAG ATTGAATTGAATTGA

AATCGATTAAAGCTT

## Fig. 18.

Human IGF-II coding sequence

```

1      met ala tyr arg pro ser glu thr leu cys gly gly glu leu val asp thr
TCTAGAATT ATG GCT TAT CGA CCA TCT GAA ACC TTG TGT GGT GGT GAG CTG GTG GAC ACC
10
20     leu gln phe val cys gly asp arg gly phe tyr phe ser arg pro ala ser arg val ser
CTC CAG TTC GTC TGT GGG GAC CGC GGT TTC TAC TTC TCT AGG CCC GCA AGC CGT GTG AGC
30
40     arg arg ser arg gly ile val glu glu cys cys phe arg ser cys asp leu ala leu leu
CGT CGC AGT CGT GGC ATC GTT GAG GAG TGC TGT TTC CGC AGC TGT GAC CTG GCC CTA TTG
50
60     glu thr tyr cys ala thr pro ala lys ser glu AM
GAA ACC TAC TGT GCT ACC CCA GCT AAG TCT GAA TAG GATCC
68

```



European Patent  
Office

# EUROPEAN SEARCH REPORT

0128733

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 84303783.9
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 7)
D,Y	THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 253, no. 8, April 25, 1978, Baltimore, US  E. RINDERKNECHT et al. "The Amino Acid Sequence of Human Insulin-like Growth Factor I and Its Structural Homology with Proinsulin" pages 2769-2776  * Page 2769 (summary); fig. 1,2 *	1	C 12 N 15/00 C 12 P 21/00 A 61 K 37/36
Y	EP - A1 - 0 026 598 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)  * Claims 2,14,24,30 *	1,3,5,7,9	
A	EP - A2 - 0 022 242 (GENENTECH, INC.)  * Claims 1,5,7,10,18 *	1,3,5,7,9	TECHNICAL FIELDS SEARCHED (Int. Cl. 7)
A	THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 250, no. 11, June 10, 1975, Baltimore, US  G. CARPENTER et al. "Characterization of the binding of <sup>125</sup> I-Labeled Epidermal Growth Factor to Human Fibroblasts" pages 4297-4304  * Pages 4297 *	4	C 12 N C 12 P A 61 K
The present search report has been drawn up for all claims			
Place of search VIENNA		Date of completion of the search 06-09-1984	Examiner WOLF
<b>CATEGORY OF CITED DOCUMENTS</b>			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons  & : member of the same patent family, corresponding document	